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Abstract	  
Chronic	  obstructive	  pulmonary	  disease	   (COPD)	   is	  a	  progressive,	   incurable	   lung	  disease	  with	  various	  systemic	  comorbidities.	  The	  COPD	  population	  has	  a	  higher	  risk	  of	  cardiovascular	  comorbidities,	  including	  stroke.	  There	  is	  some	  evidence	  to	  suggest	  worse	   outcomes	   after	   stroke	   in	   the	   COPD	  population.	   It	   has	   also	   been	  shown	   that	   pulmonary	   complications	   frequently	   occur	   after	   stroke.	   Therefore,	  the	   primary	   aims	   of	   this	   thesis	  were	   to	   investigate	  whether	   COPD	   impacts	   on	  stroke	  outcomes,	  and	  inversely,	  whether	  stroke	  causes	  acute	  lung	  injury	  in	  mice.	  	  This	   thesis	   has	   systematically	   examined	   (i)	   strain-­‐dependant	   differences	   of	  BALB/c	   and	   C57BL/6	   mice	   in	   response	   to	   an	   experimental	   model	   of	   stroke,	  transient	  middle	   cerebral	   artery	  occlusion	   (tMCAO),	   (ii)	   changes	   in	  markers	   of	  lung	   injury	   in	   mice	   following	   experimental	   stroke	   and	   (iii)	   changes	   in	   stroke	  outcomes	   in	  C57BL/6	  mice	  exposed	  acutely	  and	  chronically	   to	  cigarette	  smoke	  (preclinical	  mouse	  model	  of	  COPD).	  There	  was	  no	  observable	  difference	  in	  stroke	  outcomes	  between	  C57BL/6	  and	  BALB/c	  mice,	  however	  the	  BALB/c	  mice	  had	  a	  high	   mortality	   rate	   and	   thus	   were	   not	   used	   for	   ongoing	   studies.	   Lung	  inflammation,	  as	  measured	  through	  inflammatory	  cell	  counts	  in	  bronchoalveolar	  lavage	  fluid	  and	  proinflammatory	  gene	  expression	  in	  lung	  tissue,	  was	  elevated	  6	  h	  after	  ischaemic	  stroke.	  Further	  work	  needs	  to	  be	  done	  to	  characterise	  the	  lung	  inflammatory	   response	   to	   experimental	   ischaemic	   stroke.	   Chronic	   cigarette	  smoke	   exposure	   did	   not	   worsen	   stroke	   outcomes	   in	   this	   study.	   The	   period	   of	  smoke	  used	  in	  this	  study	  may	  have	  been	  insufficient	  to	  induce	  systemic	  changes	  believed	  to	  play	  a	  key	  role	  in	  worsened	  stroke	  outcomes.	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1.1	  Chronic	  obstructive	  pulmonary	  disease	  (COPD)	  Chronic	   obstructive	   pulmonary	   disease	   (COPD)	   is	   a	   major	   incurable	  global	   health	   burden	   and	   is	   currently	   the	   third	   largest	   cause	   of	   death	   in	   the	  world	  (1-­‐3).	   	  Much	  of	  the	  disease	  burden	  and	  health	  care	  utilisation	  in	  COPD	  is	  associated	  with	   the	  management	   of	   its	   comorbidities	   and	   infectious	   (viral	   and	  bacterial)	  exacerbations,	  known	  as	  acute	  exacerbations	  of	  COPD	  (AECOPD).	   	   In	  the	   United	   States	   alone,	   the	   medical	   costs	   attributed	   to	   COPD	   in	   2010	   were	  estimated	   to	   be	   in	   excess	   of	   $32	   billion	   (4).	   	   Comorbidities,	   defined	   as	   other	  chronic	  medical	  conditions,	  in	  particular	  cardiovascular	  disease	  markedly	  impact	  on	   disease	   morbidity,	   progression	   and	   mortality.	   	   Indeed,	   it	   is	   estimated	   that	  between	   30	   and	   50%	   of	   COPD-­‐related	   deaths	   are	   due	   to	   a	   cardiovascular	  comorbidity	   such	   as	   coronary	   artery	   disease,	   hypertension	   and	   diabetes	   (5-­‐7).  In	  addition,	  patients	  with	  COPD	  are	  at	  increased	  risk	  for	  stroke	  and	  this	  is	  even	  higher	   in	   the	   weeks	   following	   an	   AECOPD	   (8,	   9).	   Moreover,	   there	   is	   some	  evidence	   to	   suggest	   that	  COPD	   is	   associated	  not	  only	  with	  an	   increased	   risk	  of	  stroke,	  but	  worse	  outcomes	   following	   stroke	   (10,	  11).	   Importantly,	  COPD	   is	   an	  independent	  predictor	  of	  mortality	  after	  stroke	  (10).	  	  The	  mechanisms	  and	  mediators	  underlying	  COPD	  and	   its	   comorbidities,	  in	  particular	  elevated	  stroke	  risk	  and	  severity,	  are	  poorly	  understood.	  	  However,	  there	   is	   compelling	   evidence	   to	   suggest	   that	   increased	   lung	   inflammation	  oxidative	   stress	   and	   the	   “spill	   over”	   into	   the	   systemic	   circulation	   and	   play	   an	  important	   role	   in	   the	   pathophysiology	   of	   COPD	   and	   its	   comorbidities	   such	   as	  stroke.	  	  Therefore,	  while	  there	  are	  currently	  no	  effective	  therapies	  for	  reversing	  the	  lung	  pathology	  that	  is	  characteristic	  of	  COPD	  (12),	  targeting	  oxidative	  stress	  and	  lung/systemic	  inflammation	  could	  prove	  to	  be	  an	  effective	  way	  to	  treat	  the	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comorbidities	  associated	  with	  COPD	  and	  hence	   improve	  survival	  and	  quality	  of	  life	  in	  these	  patients.	  	  	  
1.2	  Overview	  of	  COPD	  pathophysiology	  COPD	   is	   a	   disease	   characterized	   by	   airflow	   limitation	   that	   is	   not	   fully	  reversible.	   	  The	  airflow	  limitation	  is	  usually	  progressive	  and	  associated	  with	  an	  abnormal	   inflammatory	   response	   of	   lungs	   to	   noxious	   particles	   and	   gases	   (13,	  14).	   	  Cigarette	  smoking	  is	  the	  major	  cause	  of	  COPD	  and	  accounts	  for	  more	  than	  95%	   of	   cases	   in	   industrialized	   countries	   (15),	   but	   other	   environmental	  pollutants	   are	   important	   causes	   in	   developing	   countries	   (16).	   	   COPD	  encompasses	   chronic	   obstructive	   bronchiolitis	  with	   fibrosis	   and	   obstruction	   of	  small	  airways,	  and	  emphysema	  with	  enlargement	  of	  airspaces	  and	  destruction	  of	  lung	   parenchyma,	   loss	   of	   lung	   elasticity,	   and	   closure	   of	   small	   airways.	   	   Most	  patients	   with	   COPD	   have	   all	   three	   pathologic	   conditions	   (chronic	   obstructive	  bronchiolitis,	   emphysema	   and	   mucus	   plugging),	   but	   the	   relative	   extent	   of	  emphysema	   and	   obstructive	   bronchiolitis	   within	   individual	   patients	   can	   vary	  (17).	   It	   is	   well	   established	   that	   a	   number	   of	   inflammatory	   cell	   types	   are	  involved	   in	   the	   pathophysiology	   of	   COPD	   including	   macrophages,	   neutrophils	  and	  T-­‐cells	  (reviewed	  in	  (17-­‐20)).	  	  These	  cells	  release	  a	  variety	  of	  mediators	  (e.g.	  tumour	   necrosis	   factor-­‐α	   (TNF-­‐α),	   monocyte	   chemotactic	   protein-­‐1	   (MCP-­‐1),	  reactive	   oxygen	   species	   (ROS),	   leukotriene	   B4	   (LTB4),	   interleukin-­‐8	   (IL-­‐8),	  granulocyte	   macrophage-­‐colony	   stimulating	   factor	   (GM-­‐CSF),	   elastolytic	  enzymes	  such	  as	  neutrophil	  elastase	  and	  matrix	  metalloproteinases)	  in	  response	  to	  cigarette	  smoke	  which	  orchestrate	  and	  perpetuate	  the	  inflammatory	  response	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in	   COPD	   (reviewed	   in	   (17-­‐20)).	   	   In	   addition	   to	   an	   increase	   in	   the	   number	   of	  macrophages	  and	  neutrophils,	  these	  cells	  appear	  to	  have	  an	  impaired	  phagocytic	  function,	  resulting	   in	   impairment	   in	  clearance	  of	  apoptotic	  cells	  and	  potentially	  contributing	   to	   the	   chronic	   inflammatory	   state	   in	   the	   lungs	   (17).	   	   The	   above	  events	   promote	   further	   inflammation	   creating	   a	   feedback	   loop	   that	   leads	   to	  chronic	   inflammation	   (17).	   Chronic	   inflammation	   induces	   repeated	   cycles	   of	  injury	   and	   repair	   that	   result	   in	   structural	   remodelling	   of	   the	   airway	   walls	  (collagen	  deposition,	  mucus	  hypersecretion),	  destruction	  of	  the	  parenchyma	  and	  alveolar	   walls	   and	   hence	   alveolar	   enlargement	   and	   emphysema	   (17).	   Once	  induced,	   the	   patients’	   condition	   progressively	   deteriorates	   with	   worsening	  inflammation,	  emphysema,	  declining	  lung	  function	  and	  increased	  breathlessness	  (12).	   	   Importantly,	   the	  mechanisms	  and	  mediators	  that	  drive	  the	   induction	  and	  progression	  of	  chronic	   inflammation,	  emphysema	  and	  altered	  lung	  function	  are	  not	   well	   understood,	   and	   this	   has	   severely	   hampered	   the	   development	   of	  effective	   treatments	   for	   COPD.	   	   In	   addition,	   current	   treatments	   have	   limited	  efficacy	   in	   inhibiting	   chronic	   inflammation,	   do	   not	   reverse	   the	   pathology	   of	  disease	   and	   fail	   to	   modify	   the	   factors	   that	   initiate	   and	   drive	   the	   long-­‐term	  progression	  of	  disease	  (20).	   	  Therefore,	  there	  is	  a	  clear	  and	  demonstrated	  need	  for	  new	  therapies	  that	  can	  prevent	  the	  induction	  and	  progression	  of	  COPD.	  
1.3	  Acute	  Exacerbations	  of	  COPD	  An	   acute	   exacerbation	   of	   COPD	   (AECOPD)	   is	   defined	   as	   “a	   sustained	  worsening	   of	   the	  patient’s	   condition,	   from	   the	   stable	   state	   and	  beyond	  normal	  day	  to	  day	  variation,	  which	  is	  acute	  in	  onset	  and	  necessitates	  change	  in	  regular	  medication	   in	   a	   patient	   with	   underlying	   COPD”	   (21).	   	   Exacerbations	   are	   a	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common	  occurrence	  in	  COPD	  patients	  and	  contribute	  mainly	  to	  morbidity,	  death	  and	   health-­‐related	   quality	   of	   life	   (21).	   	   AECOPD	   is	   a	  major	   cause	   of	   avoidable	  hospital	   admissions	   and	   often	   due	   to	   viral	   and	   bacterial	   infections	   with	   40%-­‐60%	  attributed	   to	   viral	   infections	   alone	   (21).	   	   The	  majority	   of	   these	   infections	  are	  due	  to	  respiratory	  syncytial	  virus	  (22%),	  influenza	  A	  (25%)	  and	  picornavirus	  (36%),	  with	   influenza	   having	   the	   potential	   to	   be	  more	   problematic	   due	   to	   the	  likelihood	  of	  an	  epidemic	  (21-­‐23).	  	  Respiratory	  viruses	  produce	  longer	  and	  more	  severe	  exacerbations	  and	  have	  a	  major	  impact	  on	  health	  care	  utilization	  (23,	  24).	  	  Currently,	   bronchodilator	   combinations	   modestly	   reduce	   the	   risk	   of	  exacerbation	   by	   about	   30%	   and	   are	   even	   less	   effective	   at	   preventing	   severe	  exacerbations	  that	  result	  in	  hospitalization	  (21).	  The	  understanding	  of	  the	  cellular	  and	  molecular	  mechanisms	  underlying	  AECOPD	  are	   limited,	  but	  there	   is	  an	   increase	   in	  neutrophils	  and	  concentrations	  of	   IL-­‐6,	   IL-­‐8,	   TNF-­‐α	   and	   LTB4	   in	   sputum	   during	   an	   exacerbation	   (25,	   26)	   and	  patients	  who	  have	   frequent	  exacerbations	  have	  higher	   levels	  of	   IL-­‐6	  and	   lower	  concentrations	   of	   secretory	   leukocyte	   protease	   inhibitor	   (SLPI),	   even	   when	  COPD	   is	   stable	   (27,	  28).	   	  There	   is	   also	  an	   increase	   in	   the	  activation	  of	  NFκB	   in	  alveolar	  macrophages	  during	  exacerbations	  of	  COPD	  (29),	  which	  is	  indicative	  of	  an	  inflammatory	  environment.	  
1.4	  Oxidative	  stress	  in	  COPD	  and	  AECOPD	  There	   is	   now	   extensive	   evidence	   to	   show	   that	   oxidative	   stress	   plays	   an	  important	  role	  in	  COPD	  given	  the	  increased	  oxidant	  burden	  in	  smokers	  (30,	  31).	  	  Oxidative	   stress	   is	   initiated	   by	   cigarette	   smoke	   which	   has	   more	   than	   1014	  relatively	   long-­‐lived	   oxidants/free	   radicals	   per	   puff	   (32).	   	   These	   oxidants	   give	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rise	  to	  secondary	  reactive	  oxygen	  species	  (ROS)	  by	  inflammatory	  and	  epithelial	  cells	   within	   the	   lung	   as	   part	   of	   an	   inflammatory-­‐immune	   response	   towards	   a	  pathogen	  or	  irritant.	  	  Activation	  of	  nicotinamide	  adenine	  dinucleotide	  phosphate	  (NADPH)	   oxidase	   2	   (Nox2)	   on	   macrophages,	   neutrophils	   and	   epithelium	  generates	   superoxide	   radicals	   (O2¯ˉ),	   which	   can	   then	   either	   react	   with	   nitric	  oxide	   (NO)	   to	   form	   highly	   reactive	   peroxynitrite	   molecules	   (ONOO¯ˉ)	   or	  alternatively	  be	  rapidly	  converted	  to	  damaging	  hydrogen	  peroxide	  (H2O2)	  under	  the	  influence	  of	  superoxide	  dismutase	  (SOD)	  (33-­‐36).	  	  This	  in	  turn	  can	  result	  in	  the	  non-­‐enzymatic	  production	  of	  damaging	  hydroxide	  radical	  (OH)	  from	  H2O2	  in	  the	  presence	  of	  Fe2+.	  	  Polymorphisms	  in	  extracellular	  SOD	  have	  been	  associated	  with	   reduced	   lung	   function	   and	   susceptibility	   to	   COPD	   (37).	   	   Glutathione	  peroxidases	   (Gpx)	   and	   catalase	   serve	   to	   catalyse	   toxic	   H2O2	   into	   water	   and	  oxygen.	  	  The	  ROS	  O2¯ˉ,	  ONOO¯ˉ,	  H2O2	  and	  OH	  then	  trigger	  extensive	  inflammation,	  DNA	  damage,	   protein	  denaturation	   and	   lipid	  peroxidation	   (32).	   	   Consequently,	  smokers	   and	   patients	  with	   COPD	  have	   higher	   levels	   of	   exhaled	  ROS	   than	   non-­‐smokers,	   and	   these	   levels	   are	   further	   increased	  during	   exacerbations	   (38,	   39).	  	  We	   have	   shown	   that	   loss	   of	   the	   anti-­‐oxidant	   enzyme	   Gpx-­‐1	   resulted	   in	  augmented	   cigarette	   smoke-­‐induced	   lung	   inflammation	   compared	   to	   sham-­‐exposed	  wild	  type	  mice	  and	  that	  synthetic	  repletion	  of	  Gpx	  activity	  with	  ebselen	  reduced	  cigarette	  smoke-­‐induced	  lung	  inflammation	  and	  damage	  (40).	  Alveolar	   macrophages	   obtained	   by	   BAL	   from	   the	   lungs	   of	   smokers	   are	  primed	   to	  release	  greater	  amounts	  of	  ROS	  compared	  with	   those	  obtained	   from	  non-­‐smokers	  (41).	  	  Exposure	  to	  cigarette	  smoke	  in	  vitro	  has	  also	  been	  shown	  to	  increase	   the	   oxidative	   metabolism	   of	   alveolar	   macrophages	   (42).	  	  Subpopulations	  of	  alveolar	  macrophages	  with	  a	  higher	  granular	  density	  appear	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to	   be	   more	   prevalent	   in	   the	   lungs	   of	   smokers	   and	   are	   responsible	   for	   the	  increased	  O2¯ˉ	  production	  associated	  with	  macrophages	  from	  smokers	  (42,	  43).	  	  The	  generation	  of	  ROS	  in	  epithelial	   lining	  fluid	  may	  be	  further	  enhanced	  by	  the	  presence	   of	   increased	   amounts	   of	   free	   iron	   in	   the	   pulmonary	   airspaces	   in	  smokers	   (44).	   	   This	   is	   relevant	   to	   COPD	   since	   the	   intracellular	   iron	   content	   of	  alveolar	   macrophages	   is	   increased	   in	   cigarette	   smokers	   (45).	   	   In	   addition,	  macrophages	  obtained	  from	  smokers	  release	  more	   free	   iron	   in	  vitro	   than	  those	  from	  non-­‐smokers	  (46).	  
1.5.	  Evidence	  of	  systemic	  inflammation	  and	  oxidative	  stress	  in	  
COPD	  In	  addition	  to	  lung	  inflammation,	  a	  state	  of	  chronic	  systemic	  inflammation	  is	  observed	  in	  COPD	  (47).	  	  Studies	  have	  shown	  increases	  in	  the	  serum	  levels	  of	  C-­‐reactive	   protein	   (CRP),	   fibrinogen,	   serum	   amyloid	   A	   and	   different	   pro-­‐inflammatory	  cytokines	  including	  TNF-­‐α,	  IL-­‐6	  and	  IL-­‐8	  in	  COPD	  patients	  (48-­‐50).	  	  Importantly,	   these	  markers	  of	  systemic	   inflammation	  are	  elevated	  even	   further	  during	  AECOPD	  (51).	  	  The	  origin	  of	  this	  systemic	  inflammation	  remains	  unclear.	  	  However,	  one	  explanation	   is	   that	   the	   inflammatory	   cells	   and	  pro-­‐inflammatory	  mediators	  present	  in	  the	  lungs	  “spill	  over”	  into	  the	  systemic	  circulation	  (48,	  52).	  	  This	  state	  of	  chronic	  low-­‐grade	  systemic	  inflammation	  is	  thought	  to	  contribute	  to	  the	  development	  of	  comorbidities	  of	  COPD	  (48,	  52).	  The	   contribution	   of	   systemic	   oxidative	   stress	   in	   COPD	   has	   also	   been	  recognized.	   	  There	   is	  an	   increased	  concentration	  of	  H2O2	   in	   the	  exhaled	  breath	  condensate	  (EBC)	  of	  smokers	  and	  patients	  with	  COPD	  compared	  to	  non-­‐smokers,	  and	   those	   are	   further	   increased	   during	   exacerbations	   (38,	   39).	   	   In	   addition,	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concentrations	   of	   lipid	   peroxidation	   products	   (e.g.	   8-­‐isoprostane,	   4-­‐hydroxy-­‐2-­‐nonenal,	   and	   malondialdehyde	   (MDA)),	   LTB4,	   carbon	   monoxide,	   and	  myeloperoxidase	  (MPO)	  have	  consistently	  been	  shown	  to	  be	  elevated	  in	  exhaled	  breath	  or	  exhaled	  breath	  condensate	  from	  patients	  with	  COPD	  (50,	  53).	  Systemic	  exposure	   to	   oxidative	   stress	   in	   COPD	   is	   also	   indicated	   by	   increased	   carbonyl	  adducts,	   such	   as	   4-­‐hydroxy-­‐2-­‐nonenal	   in	   respiratory	   and	   skeletal	   muscle	   (54-­‐56).	  Moreover,	  systemic	  markers	  of	  oxidative	  stress	  such	  as	  oxidized	  low-­‐density	  lipoprotein,	  advanced	  oxidation	  protein	  products,	  and	  MDA	  are	  elevated	  in	  COPD	  patients	  (57,	  58).	  In	  order	  to	  combat	  and	  neutralize	  the	  deleterious	  effects	  of	  ROS-­‐mediated	  damage,	   the	  normal	   lung	  has	  various	  endogenous	  antioxidant	  strategies,	  which	  employ	  both	  enzymatic	  and	  non-­‐enzymatic	  mechanisms.	  	  Within	  the	  lung	  lining	  fluid,	  several	  non-­‐enzymatic	  antioxidant	  species	  exist,	  which	  include	  glutathione	  (GSH),	  vitamin	  C,	  uric	  acid,	  vitamin	  E,	  and	  albumin	  (59).	  	  Enzymatic	  antioxidant	  mechanisms	  include	  SOD,	  catalase	  and	  Gpx.	   	  However,	  studies	  have	  shown	  that	  COPD	  patients	  have	  a	  systemic	  antioxidant	  imbalance,	  including	  reduced	  vitamin	  C,	  GSH	  and	  Gpx	   (53,	   60).	   	  Moreover,	   polymorphisms	   in	   extracellular	   SOD	  have	  been	  associated	  with	  reduced	  lung	  function	  and	  susceptibility	  to	  COPD	  (37).	  
1.6.	  COPD	  and	  cardiovascular	  disease	  There	  is	  evidence	  showing	  that	  patients	  with	  COPD	  have	  an	  increased	  risk	  of	   cardiovascular	   disease	   (CVD)	   and	   thus	   are	   at	   greater	   risk	   of	   dying	   from	  cardiovascular	  causes	  (48,	  61,	  62).	   	  Comorbid	  CVD	  can	  manifest	   itself	   in	  one	  or	  more	  various	  disorders	  such	  as	  angina,	  stroke,	  arrhythmias,	  hypertrophy	  of	  the	  heart,	   and	   myocardial	   infarction	   (MI),	   and	   its	   presence	   greatly	   reduces	   the	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survivability	   of	   COPD	  patients	   (63).	   	   Studies	  have	   reported	   that	  up	   to	  40	  %	  of	  deaths	   in	   COPD	   patients	   are	   due	   to	   cardiovascular	   disease	   (64-­‐67)	   and	   more	  people	   with	   mild	   to	   moderate	   COPD	   die	   of	   cardiovascular	   causes	   than	   of	  respiratory	   failure	   (61).	   	   Specifically,	   patients	   with	   COPD	   have	   a	   significantly	  higher	   risk	   of	   acute	  MI,	   arrhythmia	   and	   congestive	   heart	   failure	   (68).	   	   Over	   5	  years	   of	   follow-­‐up	   and	   compared	   with	   patients	   without	   COPD,	   patients	   with	  COPD	  had	  higher	  rates	  of	  death,	  MI,	   stroke	  and	  a	  higher	  rate	  of	  hospitalization	  due	  to	  heart	  failure,	  unstable	  angina,	  or	  arterial	  revascularization	  (69).	   	  Studies	  have	   shown	   that	   over	   50%	   of	   patients	   hospitalized	   for	   AECOPD	   have	   a	   high	  prevalence	   of	   coexisting	   CVD	   (70).	   	   It	   has	   also	   been	   demonstrated	   that	  cardiovascular	  risk	  is	  even	  more	  pronounced,	  and	  has	  a	  greater	  effect,	  during	  the	  peri-­‐exacerbation	   period	   due	   to	   further	   increases	   in	   pulmonary	   and	   systemic	  inflammation.	   	   One	   to	   five	   days	   after	   a	   severe	   exacerbation,	   the	   risk	   of	   MI	  increases	  2-­‐3	  times	  (8)	  and	  subclinical	   ischaemia	  might	  be	  even	  more	  common	  during	   these	  events,	   as	  well	   as	  during	  exacerbations	  of	  only	  moderate	   severity	  (71).	   	   A	   retrospective	   review	   examining	   24	   hour	   mortality	   following	   AECOPD	  hospitalization	   found	   that	  approximately	  60%	  of	  deaths	   that	  occurred	  resulted	  from	  cardiovascular	  causes	  (72).	   	   It	  has	  also	  recently	  been	  shown	  that	  patients	  with	  COPD	  are	  at	  increased	  risk	  for	  stroke	  and	  this	  is	  even	  higher	  (approximately	  7	  fold)	  in	  the	  weeks	  following	  an	  acute	  severe	  exacerbation	  (9).	  	  
1.7	  Overview	  of	  stroke	  pathophysiology	  In	   2013,	   stroke	   was	   the	   second-­‐leading	   global	   cause	   of	   death	   behind	   heart	  disease,	  accounting	  for	  11.8%	  of	  total	  deaths	  worldwide	  (73).	  	  Moreover,	  stroke	  is	  a	  leading	  cause	  of	  disability.	   	  Indeed,	  it	   is	  estimated	  that	  up	  to	  30%	  of	  stroke	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survivors	   do	   not	   recover	   full	   independence,	   and	   thus	   require	   assistance	   with	  self-­‐care	   for	   the	   rest	  of	   their	   lives	   (73).	   	   In	  2012,	   the	  estimated	  cost	   for	   stroke	  was	   $33	   billion	   (USA)	   and	   is	   projected	   to	   be	   $1.52	   trillion	   by	   2050	   for	   non-­‐Hispanic	  whites,	  $313	  billion	  for	  Hispanics,	  and	  $379	  billion	  for	  blacks	  (in	  2005	  USD)	  (73).	  	  Thus,	  the	  personal	  and	  economic	  burden	  of	  stroke	  is	  staggering.	  	  Ischemic	   stroke	   is	   the	   most	   common	   subtype,	   accounting	   for	  approximately	  80%	  of	  all	  strokes.	  	  This	  type	  of	  stroke	  typically	  occurs	  as	  a	  result	  of	   a	   blockage	   of	   a	   cerebral	   blood	   vessel	   by	   a	   thrombotic	   (usually	   an	  atherosclerotic	   plaque)	   or	   embolic	   clot,	   or	   as	   a	   result	   of	   cerebral	   vascular	  insufficiency	   due	   to	   structural	   (e.g.	   atherosclerosis)	   and/or	   functional	  abnormalities	  of	  cerebral	  blood	  vessels.	  Ischemic	  stroke	  can	  be	  further	  classified	  depending	  on	  the	  etiology	  such	  as	  large-­‐artery	  atherothrombosis,	  cerebral	  small	  vessel	  disease	  resulting	  in	  lacunar	  stroke,	  and	  cardioembolism.	  	  Less	  frequently,	  stroke	  can	  occur	  as	  a	  result	  of	  hemorrhage	  (intracerebral	  ~10%	  or	  subarachnoid	  ~3%)	  or	  cardiac	  arrest.	   	  There	  are	  number	  of	  traditional	  risk	  factors	  for	  stroke.	  Some	   stroke	   risk	   factors	   cannot	   be	   modified,	   for	   example	   age,	   genetic	  predisposition,	   gender	   (male),	   and	   race,	   whereas	   others	   are	   potentially	  modifiable.	  	  These	  include	  hypertension,	  hypercholesterolemia,	  atrial	  fibrillation,	  diabetes,	  and	  smoking,	  which	  account	  for	  >60%	  of	  stroke	  risk	  and	  often	  co-­‐exist	  (74).	  	  Moreover,	  as	  discussed	  above,	  lung	  diseases	  including	  COPD	  are	  emerging	  as	  ‘novel’	  stroke	  risk	  factors.	  The	  pathogenesis	  of	   ischemic	   stroke	   is	   very	   complex.	   	   In	  brain	   tissue	  of	  the	   ischemic	   core,	   which	   is	   a	   region	   characterized	   by	   a	   severe	   reduction	   in	  cerebral	   blood	   flow,	   cell	   death	  occurs	   rapidly	   and	   largely	   as	   a	   result	   of	   energy	  failure	  and	  subsequent	  necrotic	  death	   (75).	   	   Injury	   to	  brain	   tissue	  surrounding	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the	   infarct	   core	   (the	   ischemic	   penumbra),	   however,	   occurs	   over	   hours	   to	   days	  and	   multiple	   mechanisms	   are	   involved.	   	   These	   include	   excitotoxicity,	   calcium	  dysregulation,	   mitochondrial	   dysfunction,	   spreading	   depolarizations,	   and	  apoptotic	  cell	  death	  (75,	  76).	  	  Oxidative	  and	  nitrosative	  stress	  also	  play	  a	  key	  role	  in	   injury	  development	   in	   this	   region	   (77).	   	   Compelling	   evidence	   implicates	   the	  ROS-­‐generating	  NADPH	  oxidases	  as	  key	  drivers	  of	  oxidative	  stress-­‐induced	  brain	  and	  vascular	   injury	   following	  cerebral	   ischaemia	  (78-­‐82).	   	  Substantial	  evidence	  also	  supports	  the	  importance	  of	  inflammation	  and	  immune	  system	  activation	  in	  injury	   development	   and	   expansion	   after	   stroke	   (83,	   84).	   	  Moreover,	   there	   is	   a	  growing	  appreciation	  of	  the	  vascular	  contribution,	  particularly	  at	  the	  level	  of	  the	  neurovascular	   unit	   (85).	   	   The	   neurovascular	   unit	   is	   a	   collective	   term	   for	   the	  structural	  and	   functional	  association	  between	  neurons,	  perivascular	  astrocytes,	  vascular	   smooth	  muscle	   cells	   (pericytes/astrocytes),	   endothelial	   cells,	   and	   the	  basal	   lamina	   (86).	   	   Together,	   the	   components	   of	   the	   neurovascular	   unit	   act	   to	  regulate	   and	  maintain	   cerebral	   perfusion,	   preserve	   homeostatic	   balance	   in	   the	  brain,	   and	   control	   immune	   regulation.	   Furthermore,	   it	   represents	   the	   primary	  site	  of	  the	  blood-­‐brain	  barrier	  (BBB).	  	  Cerebral	  ischaemia	  has	  devastating	  effects	  on	   both	   the	   structure	   and	   functioning	   of	   the	   neurovascular	   unit.	   	   It	   impairs	  endothelial	  function	  and	  thus	  brain	  perfusion,	  disrupts	  the	  BBB	  by	  increasing	  its	  permeability,	   and	   enhances	   inflammatory	   cell	   infiltration	   (85).	   	   Collectively,	  these	  mechanisms	  contribute	  to	  and	  exacerbate	  brain	  injury	  (85).	  During	  intracerebral	  hemorrhage,	  the	  most	  common	  type	  of	  haemorrhage	  stroke,	   the	   accumulation	   of	   blood	  within	   the	   brain	   leads	   to	   rapid	   damage	   as	   a	  result	  of	  mechanical	  injury	  and	  increased	  pressure	  (87).	  	  Secondary	  damage	  can	  also	  occur	  due	   to	   the	  presence	  of	   intraparenchymal	  blood.	   	  Similar	   to	   ischemic	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stroke,	   multiple	   pathological	   pathways	   are	   involved	   including	   excitoxicity,	  oxidative	   stress,	   inflammation,	   cytotoxicity	   of	   blood,	   hypermetabolism,	   and	  disruption	  of	  the	  neurovascular	  unit	  and	  BBB	  (88).	  
1.8	  Evidence	  linking	  lung	  function,	  COPD	  and	  stroke	  
1.8.1	  Link	  between	  poor	  lung	  function	  and	  risk	  of	  cerebral	  
events	  Studies	   have	   shown	   that	   impairment	   in	   lung	   function	   is	   related	   to	   an	  increased	   risk	   of	   stroke	   (89-­‐93).	   	   Previous	   studies	   have	   shown	   that	   reduced	  forced	   expiratory	   volume	   in	   1	   second	   (FEV1)	   is	   associated	   with	   an	   increased	  incidence	   of	   both	   ischemic	   and	   haemorrhagic	   stroke,	   and	   this	   association	   is	  independent	  of	  smoking	  status.	  	  Similar	  associations	  have	  been	  observed	  linking	  reduced	   pulmonary	   function	   and	   higher	   risk	   of	   subclinical	   cerebrovascular	  abnormalities,	  including	  in	  individuals	  who	  have	  never	  smoked	  (94,	  95).	   	  These	  asymptomatic	   lesions,	   such	  as	  silent	   lacunar	   infarcts,	  white	  matter	   lesions,	  and	  cerebral	   microbleeds	   are	   considered	   to	   be	   precursors	   of	   clinical	   stroke	   and	  manifestations	   of	   cerebral	   small	   vessel	   disease	   (96-­‐98).	   	   Additionally,	  associations	  between	  lower	  FEV1	  and	  markers	  of	  subclinical	  atherosclerosis	  have	  been	   reported,	   although	   the	   relevance	   of	   this	   to	   the	   presence	   of	   subclinical	  infarcts	   and	   white	   matter	   lesions	   is	   unclear	   (99).	   	   The	   explanations	   for	   these	  observations	   are	   unclear,	   although	   impairments	   in	   lung	   function	   and	   lung	  volume	  may	  reflect	  impairments	  in	  cardiac	  function	  (100,	  101).	  
	   14	  
1.8.2	  COPD	  and	  risk	  of	  clinical	  stroke	  Recent	   studies	   have	   shown	   that	   strokes	   are	   more	   prevalent	   in	   COPD	  compared	   to	   the	   general	   population	   (102-­‐104).	   COPD	  patients	   are	   reported	   to	  have	   an	   increased	   risk	   of	   approximately	   20%	   for	   both	   ischemic	   and	  haemorrhagic	   strokes	   (9,	   68,	   105).	   	   This	   risk	   is	   estimated	   to	   be	   up	   to	   7-­‐fold	  higher	  following	  an	  AECOPD	  compared	  to	  stable	  COPD(9),	  suggesting	  that	  COPD	  itself	   is	   contributing	   to	  an	   increase	   in	   stroke	   risk,	   as	  opposed	   to	   the	   risk	  being	  solely	  due	   to	  shared	  risk	   factors.	  Consistent	  with	   this,	   studies	  have	  shown	   that	  chronic	   inflammatory	   airway	   disease	   (CIAD)	   is	   an	   independent	   risk	   factor	   for	  long-­‐term	  mortality	  post-­‐stroke	  (106).	   It	   is	  also	  known	  that	  stroke	  causes	   lung	  injury/dysfunction	   per	   se	   as	   evidenced	   by	   impaired	   cough,	   weakness	   of	  respiratory	   muscles	   and	   increase	   in	   the	   propensity	   of	   pneumonia	   (107-­‐110).	  	  Therefore,	   it	   is	   plausible	   that	   worsening	   of	   lung	   function	   due	   to	   stroke	   could	  contribute	  to	  the	  increase	  in	  long-­‐term	  mortality	  after	  stroke.	  	  
1.9	  Potential	  mechanisms	  linking	  COPD	  and	  stroke	  risk	  and	  
severity	  	  
1.9.1	  Contribution	  of	  shared	  risk	  factors	  The	   factors	   linking	   COPD	   and	   stroke	   risk	   are	   currently	   not	   fully	  understood	   and	   are	   likely	   to	   be	   interconnected	   (Figure	   1.1).	   	   It	   is	  well	   known	  that	  two	  of	  the	  most	  important	  risk	  factors	  for	  COPD,	  chronic	  cigarette	  smoking	  and	   ageing,	   are	   also	   established	   risk	   factors	   for	   stroke	   (111,	   112).	   	   Thus,	   the	  association	  between	  COPD	  and	  stroke	  may	  be	  largely	  dependent	  on	  these	  shared	  risk	   factors	   (9).	   	   Like	   other	   traditional	   stroke	   risk	   factors,	   ageing	   and	   chronic	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smoking	  increase	  the	  propensity	  to	  stroke	  by	  impairing	  the	  ability	  of	  the	  cerebral	  circulation	   to	  meet	   the	   brain’s	   high-­‐energy	   demands.	   	   This	   largely	   occurs	   as	   a	  result	  of	  structural	  and	  functional	  changes	  to	  cerebral	  blood	  vessels,	  resulting	  in	  vascular	  insufficiency	  and	  ultimately	  brain	  injury.	  	  For	  example,	  both	  risk	  factors	  often	   alter	   the	   structure	   of	   intra-­‐cranial	   and	   extra-­‐cranial	   blood	   vessels	   by	  promoting	   atherosclerosis,	   vascular	   atrophy	   and	   remodeling,	   and	   vascular	  stiffness	   (113-­‐117).	   	   Moreover,	   these	   structural	   abnormalities	   are	   typically	  accompanied	   by	   functional	   impairments	   of	   cerebral	   blood	   vessels	   resulting	   in	  alterations	  in	  cerebral	  blood	  flow	  regulation.	  Indeed,	  it	  is	  well	  documented	  that	  smoking	   (and	   nicotine)	   and	   ageing	   cause	   endothelial	   dysfunction	   (118-­‐124),	  which	   in	   turn,	   is	   associated	  with	   an	   increased	   risk	   of	   stroke	   (125,	   126).	   	   Also,	  they	   impair	   neurovascular	   coupling	   (127-­‐130),	   which	   is	   an	   essential	   adaptive	  mechanism	  that	  matches	  cerebral	  blood	  flow	  to	  neuronal	  activity.	  	  Lastly,	  ageing	  and	   smoking	   can	   disrupt	   the	   BBB	   (131-­‐133),	   which	   may	   contribute	   to	   the	  increased	  risk	  of	  intracerebral	  haemorrhage	  and	  microbleeds	  in	  COPD.	  	  Evidence	   indicates	   that	   ageing	   and	   smoking	   produce	   vascular	  impairments,	   at	   least	   in	   part,	   by	   promoting	   oxidative	   stress,	   which	   is	   driven	  primarily	   by	   the	   NADPH	   oxidases	   (122,	   123,	   127).	   	   Perhaps	   the	   best-­‐characterized	   mechanism	   by	   which	   oxidative	   stress	   can	   cause	   vascular	  dysfunction	  is	  via	  the	  inactivation	  of	  endothelial-­‐derived	  NO	  by	  O2¯ˉ	  (134).	  This	  reaction	  reduces	  the	  bioavailability	  of	  NO	  and	  thus	  nullifies	  its	  vasodilator,	  anti-­‐platelet,	   anti-­‐proliferative,	   and	   anti-­‐inflammatory	   properties.	   	   In	   addition,	   ROS	  can	  directly	  promote	  inflammation	  in	  the	  vessel	  wall	  by	  inducing	  the	  production	  of	  cytokines	  and	  pro-­‐inflammatory	  genes	  through	  the	  activation	  of	  NF-­‐κβ	  (135).	  	  Importantly,	  whereas	  oxidative	   stress	  may	   set	   the	   stage	   for	   inflammation,	   it	   in	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turn	  accentuates	  ROS	  production,	  creating	  a	  vicious	  cycle	  that	  worsens	  vascular	  dysfunction	   (76).	   	   Indeed,	   pro-­‐inflammatory	   cytokines	   such	   as	   TNFα	   and	   IL-­‐6	  alter	   the	   functioning	   of	   cerebral	   vessels	   by	   increasing	   ROS	   production	   via	   the	  NADPH	  oxidases	  (136,	  137).	  	  Moreover,	  studies	  of	  systemic	  arteries	  infer	  that	  T-­‐cells	   and	   macrophages	   also	   contribute	   (138,	   139).	   	   Oxidative	   stress	   and	  inflammation	   can	   also	   alter	   the	   structure	   of	   cerebral	   vessels	   by	   promoting	  vascular	   remodeling,	   stiffness,	   atherosclerosis,	   and	   BBB	   disruption	   (76,	   140-­‐142).	   In	  addition	  to	  producing	  vascular	  insufficiency,	  it	  is	  likely	  that	  ageing	  and	  chronic	   smoking	   modulate	   stroke	   risk	   by	   increasing	   the	   propensity	   for	  atherosclerotic	  plaque	  rupture	  (143).	  	  The	  pro-­‐thrombotic	  effects	  of	  smoking	  are	  well	   documented.	   For	   example,	   smoking	   increases	   platelet	   activation	   and	  triggers	  the	  coagulation	  cascade	  (144,	  145).	  	  Similarly,	  ageing	  is	  associated	  with	  increased	   platelet	   aggregation	   and	   enhanced	   thrombosis	   (146,	   147).	   	   Thus,	  ageing	  and	  smoking	  increase	  the	  risk	  of	  thrombotic/embolic	  events.	  
1.9.2	  Association	  with	  traditional	  stroke	  risk	  factors	  Some	  but	  not	  all	   studies	  have	   shown	   that	  an	  association	  between	  COPD	  and	   stroke	   still	   exists	   after	   adjusting	   for	   age	   and	   smoking	   status	   (9,	   98,	   105).	  	  Thus,	   although	   it	   is	   difficult	   to	   correct	   for	   the	   total	   amount	   of	   smoking	   or	  environmental	   smoke	   exposure	   (7,	   148),	   stroke	   risk	   in	   COPD	   might	   not	   be	  wholly	  explained	  by	  the	  contribution	  of	  shared	  risk	  factors.	  	  As	  discussed	  above,	  multiple	   studies	   have	   shown	   a	   link	   between	   COPD	   and	   the	   development	   of	  cardiovascular	   disease.	   	  Moreover,	   vascular/stroke	   risk	   factors	   are	   common	   in	  COPD	  patients	  including	  hypertension,	  diabetes,	  and	  hypercholesterolemia	  (149,	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150).	   	  Similar	  to	  ageing	  and	  smoking,	   these	  traditional	  risk	  factors	   increase	  the	  propensity	  to	  stroke	  by	  altering	  the	  structure	  (e.g.	  atherosclerosis	  and	  vascular	  remodelling)	   and	   functioning	   of	   vessels,	   and	   by	   increasing	   the	   propensity	   for	  atherosclerotic	  plaque	  rupture	  and	   thrombus	   formation	  (134,	  140).	   	  Moreover,	  oxidative	   (via	   the	   NADPH	   oxidases)	   and	   inflammatory	   mechanisms	   play	   vital	  roles	   in	   disease	   progression	   (151-­‐159).	   	   Thus,	   although	   the	   potential	  contributions	  of	  ageing	  and	  smoking	  cannot	  be	  ignored	  (7),	  it	  is	  conceivable	  that	  the	   systemic	   inflammation	   and	   oxidative	   stress	   in	   COPD	   may	   initiate	   and/or	  accelerate	  the	  development	  of	  traditional	  stroke	  risk	  factors,	  thereby	  leading	  to	  increased	  stroke	  risk.	  
1.9.3.	  COPD-­‐specific	  systemic	  inflammation	  and	  oxidative	  stress	  Systemic	   inflammation	   is	   emerging	   as	   a	   non-­‐traditional	   risk	   factor	   for	  stroke	  (160,	  161).	  	  For	  example,	  systemic	  markers	  of	  inflammation	  such	  as	  CRP	  and	   total	   leucocyte	   counts,	   which	   are	   both	   elevated	   in	   COPD,	   are	   predictive	  markers	  of	  ischemic	  stroke	  risk	  (162).	  	  As	  discussed,	  inflammation	  and	  oxidative	  stress	   are	   major	   drivers	   of	   cerebral	   vascular	   dysfunction.	   	   Thus,	   although	  definitive	  proof	   is	   lacking,	   it	   is	   conceivable	   that	   the	  systemic	   inflammation	  and	  increased	   oxidative	   stress	   in	   COPD	  may	   independently	   increase	   stroke	   risk	   by	  directly	  promoting	  cerebral	  vascular	  dysfunction	  and	  thus	  vascular	  insufficiency.	  	  Consistent	  with	  this	  concept,	  COPD	  is	  associated	  with	  increased	  carotid–femoral	  pulse	  wave	  velocity	  (PWV,	  the	  “gold	  standard”	  measurement	  of	  arterial	  stiffness)	  independent	   of	   cigarette	   smoke	   exposure	   (7,	   163,	   164).	   	   Treatment	   of	   COPD	  patients	  with	   an	   antioxidant	   cocktail	   (Vitamin	   C,	   Vitamin	   E,	   and	  α-­‐lipoic	   acid)	  improves	   PWV	   implicating	   a	   role	   for	   oxidative	   stress.	   	   In	   COPD	   patients	   with	  
	   18	  
frequent	   exacerbations,	   arterial	   stiffness	   increases	   and	   this	   is	   associated	   with	  inflammation	   (71).	   Importantly,	   PWV	   is	   closely	   associated	  with	   lacunar	   stroke	  and	  white	  matter	   lesions	   (165),	  which	   as	  mentioned	  are	  key	  manifestations	  of	  cerebral	  small	  vessel	  disease.	  Functional	  abnormalities	  of	  systemic	  arteries	  have	  also	   been	   reported	   in	   COPD	   patients	   compared	   with	   control	   subjects	   and	  smokers	   with	   normal	   lung	   function.	   These	   include	   impaired	   flow-­‐mediated	  dilation	  (164,	  166),	  a	  mechanism	  that	  is	  largely	  dependent	  on	  the	  production	  of	  NO	  by	   the	  endothelium.	   	  Evidence	  suggests	   that	   impairments	   in	   flow-­‐mediated	  dilation	  are	   related	   to	  CRP	   levels	  but	  not	  pack-­‐years	  of	   smoking,	   and	   that	  CRP	  levels	  are	  an	  independent	  predictor	  of	  flow-­‐mediated	  dilation,	  suggesting	  a	  role	  for	   inflammation	   (166).	   Moreover,	   an	   antioxidant	   cocktail	   improves	   flow-­‐mediated	  dilation	  in	  COPD	  patients,	  implicating	  a	  role	  for	  oxidative	  stress	  (164).	  	  Our	   knowledge	   of	   cerebral	   artery	   function	   in	   COPD	   lags	   behind	   those	  studies	   of	   systemic	   arteries.	  However,	   evidence	   thus	   far	   suggests	   that	   COPD	   is	  associated	  with	  cerebral	  vascular	  disturbances.	  	  For	  example,	  in	  an	  experimental	  model	   of	   COPD,	   activation	   of	   endothelial-­‐dependent	   dilator	   pathways	  paradoxically	   leads	   to	   constriction	   of	   cerebral	   vessels	   (e.g.	   middle	   cerebral	  artery),	   indicative	   of	   endothelial	   dysfunction	   (167).	   	   However,	   the	   roles	   of	  inflammation	   and	   oxidative	   stress	   in	   this	   dysfunction	   were	   not	   examined.	  Studies	   measuring	   cerebral	   blood	   flow	   in	   COPD	   patients	   have	   revealed	  contradictory	   findings.	   Indeed,	   some	   investigators	   have	   revealed	   that	   cerebral	  blood	  flow	  is	  reduced	  in	  COPD	  patients	  (168,	  169),	  whereas	  others	  report	  that	  it	  is	   increased	   (170,	   171).	   	   Other	   studies	   have	   focused	   on	   examining	   acute	  responses	   to	   hypercapnia	   in	   COPD	   patients.	   	   It	   is	   well	   documented	   that	   in	  healthy	  subjects,	  increased	  partial	  pressure	  of	  carbon	  dioxide	  (PaCO2)	  results	  in	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cerebral	   vascular	   dilation	   and	   increased	   cerebral	   blood	   flow.	   	   Several	  mechanisms	   are	   responsible	   including	   a	   dilatory	   response	   of	   cerebral	   arteries,	  which	   is	   largely	  dependent	  on	  NO	  production.	   	   Some	  but	  not	  all	   studies	   report	  that	   COPD	   patients	   show	   decreased	   sensitivity	   to	   hypercapnia	   (57,	   168,	   172),	  inferring	  that	  NO-­‐dependent	  cerebral	  vasodilator	  responses	  might	  be	   impaired.	  	  Consistent	  with	  this,	  one	  study	  found	  that	   these	  abnormalities	  were	  eliminated	  after	   adjustments	   were	   made	   for	   markers	   of	   oxidative	   stress,	   which	   might	  suggest	  a	  role	  for	  oxidative	  inactivation	  of	  NO	  (57).	  	  However,	  it	  is	  important	  to	  remember	   that	   central	   chemoreceptors	   and	   the	   ventilatory	   response	   are	   also	  involved	  in	  hypercapnia	  cerebral	  vascular	  responses.	  	  Thus,	  it	  is	  conceivable	  that	  impairments	  of	  these	  mechanisms	  might	  also	  contribute.	  	  Clearly,	  more	  research	  is	  needed	  to	   fully	   investigate	  the	   impact	  of	  COPD	  (independent	  of	  smoking	  and	  ageing)	  on	  the	   functioning	  of	  cerebral	  vessels,	  and	  how	  any	  such	  abnormalities	  relate	  to	  stroke	  risk.	  Recent	  evidence	  suggests	  that	  patients	  with	  COPD	  have	  increased	  platelet	  activation,	  with	   further	   activation	  occurring	  during	  AECOPD	   (173).	   	   CRP	   levels	  positively	   correlate	  with	   activation	  of	   the	   coagulation/fibrinolysis	   system	  after	  stroke,	   suggesting	   a	   link	   between	   coagulation	   and	   inflammation	   (174).	   	   Also,	  excess	   levels	   of	   ROS	   such	   as	   H2O2	  may	   lead	   to	   platelet	   hyperactivity	   and	   pro-­‐thrombotic	   phenotype	   (146).	   	   Thus,	   COPD-­‐specific	   inflammation	   and	   oxidative	  stress	  may	  also	   influence	  stroke	  risk	  by	   increasing	  susceptibility	   to	   thrombotic	  or	  embolic	  events.	  The	  link	  between	  acute	  infections	  and	  stroke	  is	  well	  documented.	  Indeed,	  numerous	   studies	  have	   shown	   that	  acute/chronic	  viral	   and	  bacterial	   infections	  are	  independent	  risk	  factors	  (161,	  175).	   	  Moreover,	  this	  mainly	  relates	  to	  acute	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respiratory	   infections	   (176).	   	   Multiple	   links	   between	   inflammation	   and	  coagulation	  may	  explain	  the	  link	  between	  infections	  and	  stroke	  per	  se	  (161,	  175).	  	  Thus,	   given	   systemic	   inflammation	   is	   elevated	   even	   further	   during	   an	   acute	  exacerbation;	  it	  is	  likely	  that	  such	  mechanisms	  may	  also	  underpin	  the	  increased	  stroke	   risk	   in	   COPD	   patients	   in	   the	   weeks	   following	   AECOPD.	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1.10	  COPD	  and	  stroke	  outcomes	  While	  many	  studies	  have	  focused	  on	  the	  increased	  risk	  of	  stroke	  in	  COPD,	  few	   studies	   have	   explored	   whether	   subjects	   with	   COPD	   have	   more	   severe	  strokes	   and	   hence	   poorer	   stroke	   outcomes.	   	   There	   is	   evidence	   to	   support	   a	  relationship	   between	   systemic	   inflammation	   and	   poor	   outcome	   in	   stroke	  patients	  and	  in	  models	  of	  experimental	  stroke.	   	  Indeed,	  experimental	  models	  of	  stroke	   have	   shown	   that	   systemic	   inflammatory	   challenges	   exacerbate	   brain	  damage	   and	   worsen	   functional	   deficits	   by	   augmenting	   cerebral	   vascular	  inflammation,	   BBB	   disruption,	   brain	   oedema,	   and	   excitotoxicity	   (177-­‐179).	  	  Moreover,	   systemic	   inflammation	   activates	   microglia	   (the	   brain’s	   resident	  immune	   cell)	   to	   induce	   cyclooxygenase-­‐dependent	   neuroinflammation	   and	  increased	  O2¯ˉ	  production	  (180).	  	  The	  mortality	  rate	  in	  stroke	  patients	  has	  been	  shown	  to	  be	  higher	  in	  those	  with	  COPD	  than	  non-­‐COPD	  patients,	  and	  COPD	  is	  an	  independent	   predictor	   of	  mortality	   following	   a	   stroke	   (10).	   Another	   study	   has	  found	  that	  exacerbations	  of	  COPD	  impact	  on	  stroke	  outcomes.	  Patients	  who	  were	  recently	  diagnosed	  with	  an	  exacerbation	  of	  COPD	  were	  more	  at	  risk	  of	  adverse	  events	   following	   a	   stroke,	   compared	   to	   those	   without	   COPD	   and	   those	   with	  stable	  COPD	  (11).	  No	  mechanistic	   link	  has	  been	  established	  between	  COPD	  and	  worse	   strokes,	   however	   it	   is	   plausible	   that	   heightened	   levels	   of	   systemic	  inflammation	   and	   oxidative	   stress	  may	   contribute	   to	   patients’	   susceptibility	   to	  brain	  injury	  and	  post-­‐stroke	  adverse	  events.	  
1.11	  Lung	  injury	  after	  stroke	  There	   is	   a	   growing	   body	   of	   evidence	   to	   suggest	   that	   patients	   are	  susceptible	  to	  pulmonary	  complications	  following	  a	  stroke,	  with	  one	  of	  the	  most	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common	   complications	   being	   pneumonia	   (181).	   Pneumonia	   increases	   short-­‐term	  mortality	  after	  stroke	  by	  approximately	  3-­‐fold	   (182),	  and	   is	  predictably	  a	  greater	   concern	   for	   those	   with	   impaired	   lung	   function,	   such	   as	   patients	   with	  COPD.	  Both	  clinical	  and	  experimental	  stroke	  induce	  an	  inflammatory	  response	  in	  the	   brain.	   Inflammatory	   products	   from	   the	   brain	   may	   spill	   over,	   through	   the	  damaged	   BBB,	   and	   produce	   a	   systemic	   inflammatory	   response.	   Studies	   have	  shown	   that	   inflammatory	   changes	   in	   the	   brain	   are	   mirrored	   in	   the	   periphery	  after	   experimental	   stroke	   in	  mice	   (183,	   184).	   Following	   the	   initial	   elevation	   in	  systemic	   inflammation,	   systemic	   immunosuppression	   occurs.	   It	   is	   feasible	   that	  these	  peripheral	   inflammatory	  changes	  may	  affect	   the	   immune	  response	  of	   the	  lungs,	  thereby	  putting	  the	  patient	  at	  risk	  of	  pneumonia.	  Acute	  lung	  injury	  (ALI)	  is	  increasingly	   becoming	   recognized	   as	   a	   significant	   contributor	   to	   mortality	   in	  patients	  that	  survive	  subarachnoid	  haemorrhage	  (SAH)	  (185).	  Although	  there	  is	  evidence	   of	  ALI	   in	   SAH,	   relatively	   little	   is	   known	  about	  ALI	   following	   ischemic	  stroke,	  which	  make	  up	  approximately	  80%	  of	  all	  strokes.	  	  
1.12	  Aims	  of	  this	  thesis	  The	   primary	   aims	   of	   this	   thesis	   were	   to	   investigate	   whether	   COPD	  impacts	   on	   stroke	   outcomes,	   and	   inversely,	   whether	   stroke	   causes	   acute	   lung	  injury	   in	   mice.	   In	   previous	   studies	   conducted	   in	   our	   laboratory,	   BALB/c	  mice	  have	  been	  used	  to	  model	  COPD,	  while	  C57BL/6	  mice	  have	  been	  used	  for	  studies	  of	  ischaemic	  stroke.	  Thus,	  a	  strain	  comparison	  study	  was	  necessary	  to	  determine	  the	   appropriate	  mouse	   strain	   for	   studies	   investigating	   the	   link	   between	   COPD	  and	  stroke.	  More	  specifically,	  this	  project	  aimed:	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1. To	   investigate	   strain-­‐dependent	   differences	   between	   BALB/c	   and	  C57BL/6	   mice	   in	   response	   to	   an	   experimental	   model	   of	   transient	  ischaemic	  stroke	  (Chapter	  3).	  2. To	   investigate	   changes	   in	   markers	   of	   lung	   injury	   in	   mice	   following	  experimental	  stroke	  in	  C57BL/6	  mice	  (Chapter	  4).	  3. To	   investigate	   changes	   in	   stroke	   outcomes	   in	   C57BL/6	   mice	   exposed	  acutely	   and	   chronically	   to	   cigarette	   smoke	   (preclinical	   mouse	  model	   of	  COPD)	  (Chapter	  5).	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2.0	  	  	  Methods	  	  The	   general	   methods	   chapter	   comprises	   of	   methods	   that	   have	   been	  applied	  over	  multiple	  chapters	  within	  this	  thesis.	  Methods	  specific	  to	  individual	  chapters	  are	  outlined	  in	  full	  in	  those	  chapters.	  
2.1	  Animals	  and	  ethics	  All	   experimental	   procedures	   were	   conducted	   in	   accordance	   with	   the	  National	  Health	  &	  Medical	  Research	  Council	  (NHMRC)	  of	  Australia	  guidelines	  for	  the	   care	   and	   use	   of	   animals	   for	   research	   and	   were	   approved	   by	   the	   RMIT	  University	  Animal	  Ethics	  Committee	  (AEC	  #1532,	  AEC	  #1349,	  AEC	  #1518).	  Male	  BALB/c	   and	  C57BL/6	  mice	   7-­‐12	  weeks	   of	   age	  were	   obtained	   from	   the	  Animal	  Resources	  Centre	  (ARC;	  Perth,	  Australia)	  and	  used	  for	  the	  experiments	  described	  below.	  	  On	  arrival	  from	  the	  ARC,	  mice	  were	  allowed	  to	  acclimatize	  for	  a	  minimum	  of	  2	  days	  before	  commencement	  of	  the	  experimental	  protocols	  described	  below.	  	  During	   the	  acclimatization	  and	  experimental	  periods,	  mice	  had	  access	   to	  water	  and	  standard	  chow	  ad	  libitum,	   and	  were	  housed	  under	  a	  12	  h	   light/	  12	  h	  dark	  cycle.	  	  
2.2	  Comparison	  of	  stroke	  outcome	  in	  two	  mouse	  strains:	  BALB/c	  
and	  C57BL/6	  	  Male	   7-­‐	   12	  week	   BALB/c	   or	   C57BL/6	  mice	  were	   randomly	   assigned	   to	  either	  sham	  or	  stroke	  surgery	  groups	  after	  1	  week.	  	  Mice	  were	  weighed	  prior	  to	  surgery	   and	   the	   day	   following	   surgery.	   Stroke	   surgeries	   were	   performed	   as	  described	  below	  with	  an	  ischaemic	  period	  of	  either	  30	  or	  50	  minutes.	  Mice	  were	  culled	  24	  h	  post-­‐surgery	  by	  anaesthetic	  overdose	  with	  isoflurane	  and	  the	  brains	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were	   rapidly	   removed	   and	   used	   for	   analysis	   including	   infarct	   and	   oedema	  analysis	  as	  described	  below.	  
2.2.1	  Focal	  cerebral	  ischaemia	  and	  reperfusion	  via	  transient	  
middle	  cerebral	  artery	  occlusion	  (tMCAO)	  The	  transient	  middle	  cerebral	  artery	  occlusion	  (tMCAO)	  model	  was	  used	  to	   induce	   stroke	   in	   mice.	   This	   is	   the	   best-­‐characterized	   model	   of	   stroke	   in	  rodents	  (186).	  Mice	  were	  anaesthetized	  with	  a	  mixture	  of	  ketamine	  (150mg/kg,	  i.p.)	   and	   xylazine	   (10mg/kg,	   i.p.)	   in	   a	   total	   volume	   of	   0.2	   ml.	   	   The	   level	   of	  anaesthesia	   was	   monitored	   throughout	   surgery,	   by	   closely	   monitoring	  respiration	  rate,	  and	  toe-­‐pinch	  response.	  	  Once	  anaesthetized,	  the	  head	  and	  neck	  were	  shaved	  and	  cleaned	  with	  betadine	  surgical	  scrub.	  An	  incision	  was	  made	  on	  the	   neck	   and	   on	   the	   skull,	   and	   a	   laser-­‐Doppler	   probe	   (Perimed,	   Sweden)	   was	  fixed	   to	   the	  skull	   to	  monitor	  regional	  cerebral	  blood	   flow	  (rCBF)	   in	   the	  area	  of	  the	  cortex	  supplied	  by	  the	  middle	  cerebral	  artery	  (~2	  mm	  posterior	  and	  5	  mm	  lateral	  to	  bregma).	  With	  the	  use	  of	  a	  dissecting	  microscope,	  the	  common	  carotid	  artery	  was	  dissected	  free.	  A	  clamp	  was	  placed	  on	  the	  common	  carotid	  artery	  and	  an	   incision	   made	   on	   the	   external	   carotid	   artery	   to	   allow	   for	   insertion	   of	   the	  filament.	   A	   6-­‐0	   nylon	   monofilament	   with	   a	   silicone-­‐coated	   tip	   (Doccol	   CO.,	  Redlands,	  CA,	  USA)	  was	  then	   inserted	   into	   the	  external	  carotid	  artery	  and	  then	  advanced	   into	  the	   internal	  carotid	  artery	  until	   it	  reached	  the	  origin	  of	   the	  MCA	  (Figure	   2.1).	   Correct	   positioning	   of	   the	   filament	   was	   confirmed	   by	   a	   >70%	  reduction	  in	  rCBF	  (Figure	  2.2).	  The	  filament	  was	  left	  in	  place	  to	  induce	  ischaemia	  for	  a	  period	  of	  30,	  40	  or	  50	  minutes	  (see	  individual	  chapters	  for	  specific	  ischemia	  duration),	  and	  then	  retracted	  to	  allow	  reperfusion	  to	  occur.	  CBF	  as	  measured	  for	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10	  minutes	  during	  reperfusion.	  Both	  the	  microtip	  and	  Laser-­‐Doppler	  probe	  were	  then	   removed.	   Prior	   to	   the	   closure	   of	  wounds,	   bupivacaine	   (0.5%	  at	   6	  mg/kg)	  was	  applied	  to	  wound	  edges.	  The	  wounds	  were	  then	  closed	  with	  surgical	  sutures	  (6-­‐0	   suture	   silk,	   B.Braun,	   Australia).	   For	   sham	   surgery,	   the	   carotid	   artery	  was	  visualized	   but	   no	   filament	   was	   inserted.	   Body	   temperature	   was	   monitored	  throughout	  surgery	  using	  a	  rectal	  probe	  (Testronics,	  Australia)	  and	  maintained	  at	  37˚C	  using	  a	  heat	  lamp	  (Exo	  Terra,	  USA)	  until	  mice	  regained	  consciousness.	  	  	  
	  Figure	  2.1:	  Path	  of	  filament	  and	  position	  of	  Laser	  Doppler	  probe	  in	  tMCAO	  model.	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  Figure	   2.2:	   Expected	   changes	   in	   regional	   cerebral	   blood	   flow	   (rCBF)	   during	  tMCAO.	   A	   drop	   in	   rCBF	   of	   >	   70%	   is	   expected	   to	   occur	   at	   time	   of	   filament	  insertion,	   and	   should	   remain	   steady	   for	   the	   duration	   of	   ischeamia.	   Upon	  withdrawal	   of	   the	   filament,	   rCBF	   should	   return	   to	   approximately	   80%	   of	   pre-­‐ischaemia	  levels.	  
2.2.2	  Neurological	  scoring	  &	  Functional	  tests	  Prior	   to	   mice	   being	   culled	   (24	   h	   or	   72	   h	   post-­‐stroke,	   see	   individual	  chapters	  for	  specific	  timepoints),	  neurological	  assessment	  was	  performed	  using	  a	  5-­‐point	  scoring	  system,	  and	  motor	  impairment	  was	  assessed	  using	  the	  hanging	  wire	   grip	   test	   as	   previously	   published	   (187,	   188).	   	   Briefly,	   neurological	   deficit	  scoring	  involved	  a	  score	  from	  0	  to	  4	  being	  assigned	  to	  each	  mouse	  according	  to	  the	   following	   criteria:	   0	   =	   normal	   motor	   function;	   1	   =	   flexion	   of	   torso	   and	  contralateral	   forelimb	  when	   lifted	   by	   the	   tail;	   2	   =	   circling	   to	   contralateral	   side	  when	  held	  loosely	  by	  the	  tail	  on	  a	  flat	  surface	  with	  normal	  posture;	  3	  =	  leaning	  on	   the	   contralateral	   side	   when	   at	   rest;	   4	   =	   uncontrolled	   circling	   or	   no	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spontaneous	  movement	  at	  rest.	  To	  assess	  motor	  impairment,	  a	  hanging	  wire	  test	  was	   used	   to	   assess	   forelimb	   grip	   strength	   (79).	   Briefly,	   this	   test	   involves	   a	  horizontal	  wire	  secured	  30	  cm	  above	  a	  padded	  surface.	  	  Mice	  were	  suspended	  by	  their	  forelimbs	  on	  this	  wire.	  The	  time	  spent	  suspended	  on	  the	  wire	  was	  recorded	  and	   the	   average	   hanging	   time	   of	   3	   trials	   with	   5	   min	   rests	   in-­‐between	   was	  calculated.	  A	  score	  of	  zero	  was	  assigned	  to	  those	  mice	  that	  fell	  immediately	  and	  a	  score	  of	  60	  was	  assigned	  to	  animals	  that	  did	  not	  fall.	  
2.2.3	  Quantification	  of	  infarct	  and	  oedema	  volumes	  Brains	  were	  collected	   from	  each	  mouse	   following	  euthanasia	  and	   frozen	  over	   liquid	  nitrogen	  6	  h	  or	  24	  h	  after	   induction	  of	  stroke.	  Coronal	  sections	  (30	  μm	   thickness;	   420	   μm	   apart)	   were	   cut	   using	   a	   cryostat	   (Leica	   Microsystems,	  Germany)	  and	  thaw	  mounted	  onto	  glass	  slides	  coated	  with	  poly-­‐l-­‐lysine	  (Thermo	  Scientific,	  USA).	  To	  quantify	  infarct	  volumes,	  tissue-­‐mounted	  slides	  were	  stained	  with	  0.1%	  thionin.	  Thionin-­‐stained	  slides	  were	  then	  imaged	  and	  infarct	  volumes	  quantified	   using	   ImageJ	   analysis	   software	   by	   correcting	   for	   oedema	   volumes	  using	  the	   following	   formula:	  CIV	  =	  [RIA	  –	  (RHA	  –	  LHA)]	  (thickness	  of	  section	  +	  distance	  between	  sections),	  where	  CIV	   is	   corrected	   infarct	  volume,	  RIA	   is	   right	  hemisphere	   infarct	   area,	   RHA	   is	   right	   hemisphere	   area	   and	   LHA	   is	   left	  hemisphere	  area.	  Oedema	  volumes	  (OV)	  are	  calculated	  using	  OV	  =	  (RHA	  –	  LHA)	  thickness	  of	  section.	  
2.3	  Effect	  of	  stroke	  on	  lung	  inflammation	  and	  lung	  injury	  Male	   7	   –	   12	  week	   old	   C57BL/6	  mice	  were	   randomly	   assigned	   to	   either	  sham	   or	   stroke	   surgery	   groups.	   Sham	   or	   stroke	   surgeries	   were	   performed	   as	  described	  above	  with	  an	  ischaemic	  period	  of	  50	  minutes.	  	  Mice	  were	  culled	  at	  6	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h,	  24	  h	  or	  72	  h	  post-­‐stroke	  by	  an	  anaesthetic	  overdose	   (sodium	  pentobarbital,	  240	  mg/kg).	  Blood	  was	  collected	  from	  the	  abdominal	  vena	  cava,	  transferred	  into	  a	  Microvette®	  collection	  tube	  (Sarstedt,	  Germany),	  and	  spun	  at	  10,000	  rpm	  for	  5	  min.	  Serum	  was	  stored	  at	  -­‐80	  °C	  for	  later	  analysis.	  The	  lungs	  were	  then	  lavaged	  as	  described	  below,	  perfused	  free	  of	  blood	  via	  right	  ventricular	  perfusion	  with	  5	  ml	  of	  PBS,	   rapidly	  excised	  en	  bloc,	   rinsed	   in	  PBS,	  blotted,	   snap	   frozen	   in	   liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C	  until	  required	  for	  PCR	  analysis.	  Brains	  were	  rapidly	  removed	  and	   frozen	  over	   liquid	  nitrogen,	   then	   stored	  at	   -­‐80	   °C	   for	   subsequent	  infarct	  and	  oedema	  analysis.	  	  
2.3.1	  Bronchoalveolar	  lavage	  and	  differential	  cell	  counts	  Lungs	  were	  	  lavaged	  in	  situ	  with	  a	  400	  μl	  aliquot	  of	  PBS,	  followed	  by	  three	  300	   μl	   aliquots	   as	   previously	   described	   (189).	   In	   total	   up	   to	   1	   ml	   of	  bronchoalvealor	  lavage	  fluid	  (BALF)	  was	  retrieved	  per	  mouse.	  	  The	  total	  number	  of	   viable	   cells	   in	   the	   BALF	   was	   determined	   using	   the	   fluorophores	   ethidium	  bromide	   and	   acridine	   orange	   (AO/EB),	   on	   a	   Nikon	   Eclipse	   E600	   (Nikon	  Instruments,	  USA).	  Cytospins	  were	  prepared	  using	  100	  μl	  of	  BALF	  spun	  at	  400	  rpm	   for	  10	  min	  using	  a	  Cytospin	  3	   (Shandon,	  UK).	  Cytospin	  preparations	  were	  then	  stained	  with	  DiffQuik	  (Dade	  Baxter,	  Australia),	  and	  500	  cells	  per	  slide	  were	  counted	   and	   differentiated	   into	   macrophages,	   neutrophils	   and	   lymphocytes	  using	  standard	  morphological	  criteria.	  	  The	  remaining	  BALF	  was	  centrifuged	  and	  the	  supernatant	  stored	  at	  -­‐80	  °C	  until	  required	  for	  further	  analysis.	  
2.4	  Effect	  of	  cigarette	  smoke	  exposure	  on	  stroke	  outcome	  Cigarette	  smoke	  (CS)	  exposure	  was	  used	  as	  a	  validated	  pre-­‐clinical	  mouse	  model	  of	  COPD.	  Male	  7-­‐12	  week	  old	  C57BL/6	  mice	  were	  randomly	  assigned	   to	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either	  sham	  (room	  air)	  or	  CS	  exposure	  groups.	  	  Mice	  were	  then	  placed	  in	  an	  18-­‐L	  perspex	   chamber	   (The	   Plastic	   Man,	   Huntingdale,	   Victoria,	   Australia)	   in	   a	  standard	  chemical	  hood	  and	  exposed	  to	  CS	  generated	  from	  9	  cigarettes	  per	  day	  for	  2,	  8	  and	  12	  weeks	  as	  previously	  described	  (189).	  Briefly,	  mice	  were	  exposed	  to	  CS	  generated	  from	  9	  cigarettes/day	  for	  2,	  8	  and	  12	  weeks	  (Monday	  to	  Friday	  but	  not	  Saturday	  and	  Sunday),	  delivered	  three	   times	  per	  day	  at	  9	  AM,	  12	  noon	  and	  3	  PM	  with	  3	  cigarettes	  spaced	  over	  1	  h.	  Smoke	  was	  generated	  in	  50-­‐ml	  tidal	  volumes	   over	   10	   s,	   by	   use	   of	   timed	   draw-­‐back	   mimicking	   normal	   smoking	  inhalation	  volume	  and	  cigarette	  burn	  rate.	  The	  mean	  total	  suspended	  particulate	  mass	   concentration	   in	   the	   chamber	   containing	   CS	   was	   ~420	   mg	   m−3	   (189).	  Commercially	   available	   filter-­‐tipped	  Winfield	   Red	   cigarettes	   (manufactured	   by	  Philip	  Morris,	  Australia)	  of	  the	  following	  composition	  were	  used:	  16	  mg	  or	  less	  of	  tar,	  1.2	  mg	  or	  less	  of	  nicotine,	  and	  15	  mg	  or	  less	  of	  CO.	  Sham-­‐exposed	  mice	  were	  placed	  in	  an	  18-­‐L	  perspex	  chamber	  but	  were	  not	  exposed	  to	  CS.	  After	   a	   CS-­‐exposure	   period	   of	   2,	   8	   or	   12	   weeks,	   mice	   were	   randomly	  allocated	   to	   sham	   or	   stroke	   surgery	   groups.	   	   Sham	   or	   stroke	   surgeries	   were	  performed	  with	   an	   ischaemic	   period	   of	   40	  min	   or	   50	  min	   as	   described	   above.	  	  Mice	   were	   culled	   at	   24	   h	   post-­‐stroke	   by	   an	   anaesthetic	   overdose	   (sodium	  pentobarbital,	  240	  mg/kg).	  	  Brains	  were	  rapidly	  removed	  and	  frozen	  over	  liquid	  nitrogen,	  then	  stored	  at	  -­‐80	  °C	  for	  subsequent	  analysis.	  	  Blood	  was	  collected	  from	  the	   abdominal	   vena	   cava,	   transferred	   into	   a	   Microvette®	   collection	   tube	  (Sarstedt,	  Germany),	  and	  spun	  at	  10,000	  rpm	  for	  5	  min.	  Serum	  was	  stored	  at	   -­‐80°C	  for	  later	  analysis.	  The	  lungs	  were	  then	  lavaged	  as	  described	  above,	  perfused	  free	  of	  blood	  via	  right	  ventricular	  perfusion	  with	  5	  ml	  of	  PBS,	  rapidly	  excised	  en	  bloc,	   rinsed	   in	  PBS,	  blotted,	  snap	   frozen	   in	   liquid	  nitrogen	  and	  stored	  at	   -­‐80	  °C	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until	   required	   for	   PCR	   analysis.	   Brains	  were	   rapidly	   removed	   and	   frozen	   over	  liquid	  nitrogen,	  then	  stored	  at	  -­‐80	  °C	  for	  subsequent	  infarct	  and	  oedema	  analysis.	  	  	  
2.4.1	  RNA	  extraction	  Lungs	   from	   individual	   mice	   were	   crushed	   to	   a	   fine	   powder	   in	   liquid	  nitrogen	  with	  a	  mortar	  and	  pestle,	  and	  subsequently	  homogenised	  by	  passing	  5	  times	  through	  a	  21G	  needle	  with	  a	  1	  ml	  syringe.	  Total	  RNA	  was	  extracted	  from	  lung	   samples	   using	   an	   RNeasy	   Plus	   kit	   (QIAGEN,	   Australia),	   according	   to	   the	  manufacturer’s	   instructions.	   	   RNA	   yield	   and	   purity	   were	   quantified	   using	   a	  	  nanodrop	   (ND-­‐1000,	   Biolab).	   	   Total	   RNA	   from	   lung	   samples	   were	   reverse	  transcribed	  to	  cDNA	  (Applied	  Biosystems	  High	  Capacity	  RNA-­‐to-­‐cDNA	  Kit,	  USA).	  Quantitative	   polymerase	   chain	   reaction	   (qPCR)	   was	   performed	   using	   mouse-­‐specific	  TaqMan®	  Gene	  Expression	  Assays	  (Applied	  Biosystems,	  USA),	  on	  an	  ABI	  7900HT	   Sequence	   Detection	   System.	   Samples	   were	   assayed	   in	   triplicate	   and	  negative	   reverse-­‐transcriptase	   controls	   were	   included.	   Fold	   change	   was	  determined	   in	   comparison	   to	   the	   sham	   control	   group,	   after	   standardising	   to	  GAPDH	  (housekeeping	  gene),	  using	  the	  standard	  Delta-­‐Delta	  CT	  method	  (190).	  
2.5	  Data	  and	  statistical	  analysis	  All	  statistical	  analysis	  was	  performed	  using	  GraphPad	  Prism	  6	  (GraphPad	  Software,	  Version	  6.07,	  La	  Jolla,	  CA,	  USA).	  	  Results	  are	  presented	  as	  mean	  ±	  SEM	  and	  a	  P<0.05	  was	  considered	  to	  be	  statistically	  significant.	  Mouse	  weights	  were	  compared	  with	   two-­‐way	  ANOVA,	   repeated	  measures	  with	   Bonferroni	   post-­‐hoc	  test.	   	   Infarct	   and	   oedema	   volumes,	   BALF,	   and	   qPCR	   were	   analysed	   using	   an	  unpaired	  t-­‐test.	  See	  experimental	  chapters	  for	  specific	  statistical	  analyses	  of	  data.	  	   	  




Comparison	  of	  stroke	  outcome	  in	  two	  mouse	  
strains:	  BALB/c	  and	  C57BL/6	  	   	  
	   34	  
3.1	  Introduction	  The	   mechanisms	   underlying	   stroke	   have	   been	   studied	   in	   a	   number	   of	  animal	  models	  (191);	  however	  there	  has	  been	  little	  success	  in	  the	  development	  of	  treatments	  and	  neuro-­‐protective	  agents	  for	  human	  disease.	  	  Many	  treatments	  that	  have	  shown	  effectiveness	  in	  animal	  models	  have	  proved	  to	  be	  ineffective	  in	  human	  trials	  (192).	  The	  success	  of	  stroke	  studies	  depends	  upon	  the	  selection	  of	  the	   most	   appropriate	   animal	   model,	   for	   results	   to	   be	   translatable	   to	   human	  disease.	  There	  are	  countless	  factors	  that	  contribute	  to	  the	  selection	  of	  the	  most	  suitable	   animal	   model	   for	   any	   given	   experiment.	   There	   are	   a	   number	   of	  established	   animal	   models	   used	   for	   studying	   the	   mechanisms	   of	   stroke,	   each	  with	  their	  own	  advantages	  and	  limitations	  (191,	  193).	  Ischaemic	  stroke,	  the	  most	  common	   subtype	   of	   human	   stroke	   (194),	   can	   be	   modeled	   in	   animals	   by	  transiently	  or	  permanently	  blocking	  blood	   flow	   in	  a	  cerebral	  artery.	  Mice	  are	  a	  popular	   choice	   of	   animal	   for	   stroke	   research	   for	   a	   number	   of	   reasons:	   it	   is	  considered	   more	   ethical	   to	   use	   smaller	   rodents	   over	   other	   species;	   the	  maintenance	   cost	   of	  mice	   is	   comparatively	   low;	   reagents	   for	  mouse	  molecular	  work	  are	  cheaper;	  and	  their	  response	  to	   ischaemic	  stroke	   is	  well	  characterized	  (186).	  	  The	   choice	   of	   strain	   of	   mouse	   is	   important	   for	   studies	   exploring	   the	  mechanisms	   underlying	   stroke.	   Susceptibility	   to	   damage	   from	   cerebral	  ischaemia	  varies	  between	  strains	  of	  mice.	  Barone	  et	  al	  (195)	  showed	  significant	  differences	   in	   cerebral	   infarct	   volumes	   in	   response	   to	   cerebral	   ischaemia,	  between	   B6D2F1	   (BDF1),	   Swiss	   Webster	   (CFW)	   and	   BALB/c	   mouse	   strains,	  demonstrating	  that	  the	  BALB/c	  mouse	  strain	  had	  an	  increased	  degree	  of	  cerebral	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damage	  following	  focal	  ischaemia.	  The	  C57BL/6	  mouse	  strain	  appears	  to	  be	  the	  most	  susceptible	  to	  cerebral	  ischaemia,	  with	  highly	  reproducible	  lesions	  (196).	  To	  effectively	  study	  how	  COPD	  impacts	  upon	  stroke	  outcomes,	  an	  animal	  model	   must	   be	   used	   that	   effectively	   mimics	   the	   relevant	   aspects	   of	   COPD	   in	  humans,	  while	  also	  being	  a	  relevant	  model	  of	  experimental	  stroke.	  The	  BALB/c	  mouse	   strain	   is	   typically	   used	   in	   COPD	   research,	   as	   the	   response	   to	   cigarette	  smoke	  (the	  major	  risk	  factor	  for	  the	  development	  of	  COPD)	  mimics	  many	  aspects	  of	  human	  disease,	  such	  as	  chronic	  lung	  inflammation	  and	  impaired	  lung	  function	  (189,	   197).	   Although	   C57BL/6	   mice	   are	   widely	   used	   in	   experimental	   stroke	  research	   (198),	   no	   study	   has	   yet	   compared	   cerebral	   damage	   after	   ischaemic	  stroke	  between	  C57BL/6	  mice	  and	  BALB/c	  mice.	  	  Therefore,	   the	   aim	   of	   this	   experimental	   chapter	   was	   to	   use	   the	   tMCAO	  model	   of	   stroke	   to	   compare	   stroke	   outcomes	   (neurological	   and	   functional	  impairment,	   infarct	   and	   oedema	   volumes)	   in	   C57BL/6	   and	   BALB/c	   mice	   to	  determine	  which	  strain	  of	  mouse	  should	  be	  used	  for	  the	  experiments	  described	  in	  Chapter	  5	  (i.e.	  the	  impact	  of	  cigarette	  smoke	  exposure	  on	  stroke	  outcomes).	  It	  was	   hypothesised	   that	   BALB/c	   mice	   would	   have	   worse	   stroke	   outcomes	  compared	   to	   C57BL/6	  mice,	   and	   that	   a	   shorter	   period	   of	   ischaemia	   would	   be	  required	  to	  elicit	  the	  ideal	  infarct	  volume	  of	  35	  –	  40	  mm3.	  This	  volume	  is	  ideal	  as	  both	   increases	  and	  decreases	   in	   infarct	  volume	  can	  be	  observed	  (199)	  .	  BALB/c	  mice	   were	   expected	   to	   have	   worse	   stroke	   outcomes	   based	   on	   previous	   that	  suggest	   BALB/c	   mice	   are	   more	   susceptible	   to	   brain	   injury	   following	   ischemic	  stroke	   when	   compared	   to	   other	   strains,	   largely	   due	   to	   variations	   in	  cerebrovascular	  anatomy.	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3.2	  Materials	  and	  methods	  Common	  materials	  and	  solutions	  are	  listed	  in	  General	  Methods	  (Chapter	  2).	  
3.2.1	  Animals	  and	  ethics	  All	   experimental	   procedures	   were	   approved	   by	   the	   Animal	   Ethics	  Committee	   at	  RMIT	  University	   (AEC	  #1518).	   C57BL/6	  mice	  7-­‐12	  weeks	  of	   age	  were	   obtained	   from	   the	   Animal	   Resources	   Centre	   (ARC;	   Perth,	   Australia)	   and	  used	  for	  the	  experiments	  described	  below.	  
3.2.2	  Experimental	  protocols	  C57BL/6	   mice	   and	   BALB/c	   mice	   underwent	   tMCAO	   surgery	   with	   an	  ischaemic	  period	  of	  30	  min	  (n	  =	  18	  for	  BALB/c;	  n	  =	  20	  for	  C57BL/6)	  or	  50	  min	  (n	  =	  10	  for	  BALB/c;	  n	  =	  16	  for	  C57BL/6)	  as	  outlined	  in	  Chapter	  2:	  General	  Methods.	  	  Regional	  cerebral	  blood	  flow	  was	  measured	  during	  the	  procedure	  for	  all	  stroke	  animals,	  using	  trans-­‐cranial	   laser-­‐Doppler	  flowmetry.	   	  Sham	  animals	  (C57BL/6,	  n	   =	   7)	   underwent	   the	   same	   procedure	   except	   the	   filament	   was	   not	   inserted.	  Functional	   and	   neurological	   tests	   were	   performed	   as	   described	   in	   Chapter	   2:	  General	  Methods,	  just	  prior	  to	  culling.	  Mice	  were	  culled	  via	  anaesthetic	  overdose	  with	   isoflurane,	   24	  h	   following	   the	   induction	  of	   ischaemia.	   Samples	   (lungs	   and	  brain)	  were	  collected	  as	  described	  in	  Chapter	  2:	  General	  Methods.	  	  
3.3	  Results	  
3.3.1	  Degree	  of	  hypoperfusion	  after	  stroke	  Following	   insertion	   of	   the	   monofilament	   at	   the	   origin	   of	   the	   MCA,	   all	  stroke	  mice	  experienced	  a	  similar	  drop	  (~75%)	  in	  regional	  cerebral	  blood	  flow	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(Figure	  3.1).	  This	  remained	  steady	  over	  the	  ischaemic	  period	  for	  all	  groups.	  Both	  strains	   of	  mice	   had	   a	   similar	   degree	   of	   reperfusion	   after	   30	  min	   of	   ischaemia	  (~80%	   of	   initial	   blood	   flow	   in	   C57BL/6	   mice,	   ~90%	   in	   BALB/c	   mice),	   and	   a	  similar	  degree	  of	  reperfusion	  after	  50	  min	  of	  ischaemia	  (~100%	  of	  initial	  blood	  flow	  in	  C57BL/6	  mice,	  	  ~125%	  of	  initial	  blood	  flow	  in	  BALB/c	  mice).	  
	  Figure	   3.1:	   Regional	   cerebral	   blood	   flow	   during	   tMCAO	   surgery	   and	   during	  reperfusion.	  	  Ischaemic	  periods	  of	  30	  min	  (A,	  n	  =	  8	  -­‐	  9)	  and	  50	  min	  (B,	  n=	  5	  -­‐	  8)	  were	  used.	  All	  results	  expressed	  as	  mean	  ±	  SEM.	  (P>0.05,	  Student’s	  paired	  t-­‐test).	  
3.3.2	  Stroke	  outcomes	  in	  C57BL/6	  and	  BALB/c	  mice	  	  Stroke	  mice	  with	  an	  ischaemic	  period	  of	  30	  min	  had	  reduced	  hanging	  grip	  time	  when	  compared	  to	  sham	  animals,	  but	  this	  was	  not	  significant,	  and	  there	  was	  no	   difference	   between	   mouse	   strains	   (Figure	   3.2A).	   Both	   the	   C57BL/6	   and	  BALB/c	  strains	  of	  mice	  displayed	  a	  significant	  neurological	  deficit	  after	  a	  stroke	  with	   an	   ischaemic	   period	   of	   30	  min,	   compared	   to	   sham	   animals	   (Figure	   3.2B,	  P<0.05).	  However,	  BALB/c	  mice	  were	  significantly	   less	  neurologically	   impaired	  compared	   to	   C57BL/6	   mice	   (Figure	   3.2B,	   P<0.05).	   C57BL/6	   mice	   have	   a	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mortality	   rate	   of	   8-­‐10%	   following	   tMCAO	   surgery	   in	   studies	   previously	  conducted	  in	  our	  laboratory.	  In	  this	  study,	  C57BL/6	  mice	  had	  a	  mortality	  rate	  of	  20%	  in	  the	  30	  min	  ischaemia	  group	  (4/20),	  and	  a	  mortality	  rate	  of	  19%	  in	  the	  50	  min	  ischaemic	  group	  (3/16).	  BALB/c	  mice	  had	  a	  mortality	  rate	  of	  39%	  in	  the	  30	  min	   ischaemia	   group	   (7/18),	   and	   a	   mortality	   rate	   of	   40%	   in	   the	   50	   min	  ischaemia	  group	  (4/10).	  	  
	  Figure	   3.2:	  Hanging	  wire	   (A)	   and	   neurological	   (B)	   scores	   after	   tMCAO	   surgery	  with	   an	   ischaemic	   period	   of	   30	  minutes	   in	   C57BL/6	  mice	   (n	   =	   8)	   and	  BALB/c	  mice	  (n	  =	  9),	  and	  in	  C57BL/6	  mice	  after	  a	  sham	  procedure	  (n	  =	  8).	  Hanging	  wire	  results	  are	  expressed	  as	  mean	  ±	  SEM	  (one-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐hoc	  test),	  neurological	  deficit	  score	  results	  expressed	  as	  median	  (*P	  <	  0.05	  vs.	  sham,	  #P	  0.05	  vs.	  C57BL/6,	  Mann-­‐Whitney	  test)	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3.3.3	  Cerebral	  infarct	  and	  oedema	  volumes	  in	  C57BL/6	  and	  
BALB/c	  mice	  Thionin	  staining	  of	   coronal	  brain	  sections	  24	  h	  post-­‐stroke	  showed	   that	  BALB/c	  mice	  experienced	  similar	   cerebral	  damage	  compared	   to	  C57BL/6	  mice	  (Figure	  3.3).	  	  	  
	  Figure	  3.3:	  Representative	   thionin-­‐stained	   coronal	   brain	   sections	   at	   24	  h	  post-­‐stroke.	   BALB/c	   and	   C57BL/6	   mice	   underwent	   tMCAO	   procedure	   with	   an	  ischaemic	  period	  of	  30	  min	  or	  50	  min.	  Area	  of	  infarct	  is	  shown	  circled	  in	  yellow.	  
30 min ischaemia 50 min ischaemia 
BALB/c 
C57BL6/J 
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Cerebral	   infarct	   volumes	  were	   typically	   smaller	   in	  BALB/c	  mice	   (Figure	  3.4A	  &	  B	  P>0.05)	   for	  both	  30	  and	  50	  min	   ischaemic	  periods,	  however	   this	  was	  not	   significant.	   The	   same	   pattern	   was	   also	   observed	   for	   cerebral	   oedema	  volumes	  (Figure	  3.4B	  &	  D,	  P>0.05).	  	  
	  Figure	  3.4:	  Cerebral	  infarct	  and	  oedema	  volumes	  at	  24	  h	  after	  tMCAO	  procedure	  with	  ischaemic	  periods	  of	  30	  min	  (A,	  B;	  n	  =	  9	  for	  BALB/c,	  n	  =	  6	  for	  C57BL/6)	  and	  50	  min	  (C,	  D;	  n	  =	  5	  for	  BALB/c,	  n	  =	  9	  for	  C57BL/6).	  All	  results	  are	  expressed	  as	  mean	  ±	  SEM	  (Student’s	  t-­‐test).	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to	   use	   in	   subsequent	   long-­‐term	   smoke	   exposure	   studies.	   It	   was	   expected	   that	  BALB/c	  mice	  would	  be	  more	  sensitive	  to	  cerebral	  ischaemia	  than	  C57BL/6	  mice.	  Previous	  studies	  have	  shown	  BALB/c	  mice	  to	  have	  larger	  infarcts	  in	  response	  to	  cerebral	   ischaemia	  when	   compared	   to	  other	  mouse	   strains	   (195).	  This	  may	  be	  due	   to	   a	   lack	   of	   posterior	   communicating	   arteries	   in	   the	  BALB/c	  mouse	   brain,	  which	  makes	  at	  an	  increased	  risk	  of	  damage	  but	  also	  suggests	  that	  they	  are	  the	  most	  consistent	  in	  terms	  of	  post-­‐stroke	  outcomes(195).	  	  This	  study	  was	  limited	  in	  that	  no	  BALB/c	  sham	  mice	  were	  included,	  and	  so	  comparisons	  to	  sham	  mice	  were	  made	  to	  C57BL/6	  mice.	  Thus,	  there	  may	  be	  strain	  differences	  in	  the	  hanging	  wire	  test	  that	  are	  not	  shown	  in	  this	  study.	  	  I	  saw	  no	  differences	  in	  rCBF	  between	  the	  two	  strains	  of	  mice	  throughout	  the	   stroke	   surgery.	   This	   indicates	   that	   both	   strains	   of	   mice	   had	   a	   similar	  reduction	  in	  blood	  flow,	  and	  thus	  stroke	  damage	  should	  be	  comparable.	  It	  has	  been	  suggested	  that	   the	  sensitivity	  of	   the	  BALB/c	  mouse	  strain	  to	  cerebral	   ischaemia	   is	   due	   to	   a	   variation	   in	   the	   cerebrovascular	   anatomy	  compared	   to	   other	   strains	   of	   mice.	   BALB/c	   mice	   have	   non-­‐existent	   or	   non-­‐functional	   posterior	   communicating	   arteries(195),	   which	   create	   a	   secondary	  supply	  of	  blood	  to	  the	  area	  of	  the	  brain	  normally	  supplied	  by	  the	  middle	  cerebral	  artery.	   This	   lack	   of	   collateral	   blood	   supply	   may	   lead	   to	   the	   development	   of	  greater	   infarcts,	   and	   perhaps	   contributes	   to	   the	   elevated	   mortality	   rate	   in	  BALB/c	   mice.	   It	   also	   makes	   them	   a	   more	   consistent	   and	   potentially	   reliable	  model	  of	  cerebral	  ischaemia,	  as	  the	  brain	  is	  more	  sensitive	  to	  damage.	  Despite	   evidence	   to	   suggest	   BALB/c	   mice	   would	   be	   more	   sensitive	   to	  cerebral	  ischaemia,	  no	  worsening	  of	  stroke	  outcomes	  was	  observed	  compared	  to	  C57BL/6	  mice.	  The	  only	  significant	  difference	  between	  the	  strains	  of	  mice	  was	  a	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lower	   neurological	   score	   in	   BALB/c	  mice	   compared	   to	   C57BL/6	  mice.	   BALB/c	  mice	   generally	   had	   smaller	   infarct	   and	   oedema	   volumes	   than	   C57BL/6	   mice,	  although	  differences	  were	  not	   significant.	  This	   suggests	   that	  BALB/c	  mice	  may	  be	   more	   resistant	   to	   MCAO	   when	   compared	   to	   C57BL/6	   mice.	   The	   most	  significant	   finding	   from	   this	   study	  was	   that	   BALB/c	  mice	   had	   a	   high	  mortality	  rate	  after	  stroke.	  This	  may	  have	  skewed	  the	  results	  of	   this	  study;	  BALB/c	  mice	  that	  did	  not	  survive	  to	  24	  h	  post	  surgery	  may	  have	  suffered	  substantial	  cerebral	  damage.	   It	   may	   be	   that	   the	   BALB/c	   mice	   who	   survived	   were	   resistant	   to	  ischaemia,	   and	   that	   BALB/c	   mice	   express	   an	   ‘all-­‐or-­‐nothing’	   response	   to	  ischaemia.	   This	   present	   study	   has	   shown	   that	   BALB/c	   mice	   would	   be	   an	  inappropriate	  choice	  of	  mouse	  strain	  for	  a	  long-­‐term	  smoke-­‐exposure	  study,	  due	  to	   the	  mortality	   rates	   observed.	   C57BL/6	  mice	   will	   thus	   be	   used	   in	   following	  studies.	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4.1	  Introduction	  Pulmonary	  complications	  such	  as	  pneumonia,	  acute	  lung	  injury	  (ALI)	  and	  neurogenic	   pulmonary	   oedema	   (NPO)	   frequently	   occur	   in	   the	   first	   few	  weeks	  following	   a	   stroke	   (181,	   185,	   200,	   201).	   These	   complications	   are	   a	   major	  contributor	   to	   morbidity	   and	   mortality	   (202,	   203).	   ALI,	   an	   acute	   and	   severe	  hypoxia,	   is	   commonly	   associated	   with	   various	   forms	   of	   brain	   injury,	   and	   is	  estimated	   to	   occur	   in	   5	   –	   30%	   of	   patients	   with	   subarachnoid	   haemorrhage,	   a	  subtype	  of	  stroke	  (185,	  201,	  204).	  The	  incidence	  of	  ALI	  after	  ischaemic	  stroke	  is	  unclear,	   however	   one	   study	   reported	   acute	   respiratory	   distress	   syndrome	   (a	  more	  severe	  form	  of	  ALI)	  in	  4%	  of	  ischaemic	  stroke	  patients	  (205).	  	  	  NPO	   is	   defined	   as	   bilateral	   pulmonary	   oedema	   that	   occurs	   following	   a	  neurological	   insult,	  and	   it	  has	  been	  recognized	   in	  various	   forms	  of	  brain	   injury	  (206).	   The	  mechanisms	   involved	   in	  NPO	   continue	   to	   be	  debated;	   however	   one	  possible	  mechanism	  is	  the	  “blast	   injury	  theory”.	  Damage	  to	  the	  central	  nervous	  system	   initiates	   a	   massive	   sympathetic	   discharge,	   known	   as	   a	   sympathetic	  “storm”	  (207).	  This	  leads	  to	  systemic	  vasoconstriction,	  and	  subsequently	  a	  shift	  of	  blood	  to	  the	  pulmonary	  circulation	  due	  to	  their	   low	  resistance.	  This	   leads	  to	  increased	  pulmonary	  capillary	  pressure,	  damaging	  the	  capillary	  epithelium	  and	  causing	  pulmonary	  oedema	  (204).	   It	   is	  also	  believed	  that	  the	  over-­‐activation	  of	  the	   sympathetic	   nervous	   system	   initiates	   a	   systemic	   inflammatory	   response,	  with	   infiltration	   of	   activated	   neutrophils	   and	   macrophages	   into	   the	   alveolar	  spaces	   (204,	   208).	   A	   “double-­‐hit”	   model	   has	   been	   proposed	   to	   describe	   the	  mechanism	   through	  which	   lung	   failure	   and	   pulmonary	   complications	   occur	   in	  ischaemic	  stroke	  (204).	  The	  initial	  sympathetic	  storm	  damages	  the	  lungs,	  making	  them	  more	  susceptible	  to	  further	  damage	  (first	  hit).	  Immunosuppression	  occurs	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as	   early	   as	   12	   hours	   following	   a	   stroke,	  making	   the	   lungs	  more	   susceptible	   to	  infection	  and	  pneumonia	  (second	  hit).	  Currently,	   studies	  exploring	   the	   time-­‐course	  of	  pulmonary	   inflammation	  following	   ischaemic	   stroke	   are	   limited.	   Inflammatory	   cell	   counts	   in	   BAL	   have	  been	  measured	  24	  hours	   after	   experimental	   stroke	   in	  mice	   (209),	   however	  24	  hours	  post-­‐stroke	  may	  be	  too	  late	  to	  observe	  inflammation	  leading	  to	  lung	  injury.	  Levels	   of	   inflammatory	   cytokines	   such	   as	   TNF-­‐α,	   IL-­‐6	   and	   IL-­‐1β	   appeared	   to	  increase	  in	  the	  lungs	  of	  uninfected	  mice	  4	  h	  after	  stroke	  (210).	  It	  has	  also	  been	  shown	   that	   the	   peripheral	   inflammatory	   response	   induced	   by	   stroke,	   peaks	   4	  hours	  after	  the	  stroke	  (184).	  These	  findings	  suggest	  that	  an	  investigation	  of	  lung	  inflammation	  and	   injury	   induced	  by	  stroke	  would	  need	   to	  draw	  a	   focus	  on	   the	  hours	  shortly	  after	  a	  stroke.	  This	  current	  study	  aims	  to	  investigate	  inflammatory	  changes	  in	  the	  lungs	  following	   experimental	   ischaemic	   stroke	   in	   mice,	   in	   the	   period	   shortly	   after	  stroke	  (6	  h)	  and	  24	  h	  following	  stroke.	  It	  was	  hypothesized	  that	  we	  would	  see	  an	  initial	  increase	  in	  lung	  inflammation	  at	  6	  h,	  with	  lung	  inflammation	  decreasing	  by	  24	  h	  post-­‐stroke.	  
4.2	  Materials	  and	  methods	  Common	  materials	  and	  solutions	  are	  listed	  in	  General	  Methods	  (Chapter	  2).	  
4.2.1	  Animals	  and	  ethics	  All	   experimental	   procedures	   were	   approved	   by	   the	   Animal	   Ethics	  Committee	   at	  RMIT	  University	   (AEC	  #1349).	   C57BL/6	  mice	  7-­‐12	  weeks	  of	   age	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were	   obtained	   from	   the	   Animal	   Resources	   Centre	   (ARC;	   Perth,	   Australia)	   and	  used	  for	  the	  experiments	  described	  below.	  
4.2.2	  Experimental	  protocols	  Mice	   underwent	   tMCAO	   surgery	  with	   an	   ischaemic	   period	   of	   50	  min	   as	  outlined	   in	   Chapter	   2:	   General	   Methods.	   	   Regional	   cerebral	   blood	   flow	   was	  measured	  during	  the	  procedure	  for	  all	  stroke	  animals,	  using	  trans-­‐cranial	  laser-­‐Doppler	   flowmetry.	   	   Sham	   animals	   underwent	   the	   same	   procedure	   except	   the	  filament	  was	  not	  inserted.	  Functional	  and	  neurological	  tests	  were	  performed	  as	  described	  in	  Chapter	  2:	  General	  Methods,	  just	  prior	  to	  culling.	  Mice	  were	  culled	  via	   anaesthetic	   overdose	   with	   sodium	   pentobarbital	   (240mg/kg),	   6	   h	   or	   24	   h	  following	   the	   induction	   of	   ischaemia.	   Samples	   (BALf,	   lungs	   and	   brain)	   were	  collected	  as	  described	  in	  Chapter	  2:	  General	  Methods.	  	  
4.3	  Results	  
4.3.1	  Degree	  of	  hypoperfusion	  after	  stroke	  Following	   insertion	   of	   the	   monofilament	   at	   the	   origin	   of	   the	   MCA,	   all	  stroke	  mice	  experienced	  a	  similar	  drop	  (~75%)	  in	  regional	  cerebral	  blood	  flow	  (Figure	  4.1).	  This	  remained	  steady	  over	  the	  ischaemic	  period	  for	  both	  the	  6	  h	  and	  24	  h	  groups.	  A	  similar	  degree	  of	  reperfusion	  (~100%)	  was	  observed	  in	  all	  mice	  across	  the	  15	  min	  reperfusion	  period.	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  Figure	   4.1:	   Regional	   cerebral	   blood	   flow	   during	   tMCAO	   surgery	   and	   during	  reperfusion.	   Procedures	   were	   performed	   with	   an	   ischaemic	   period	   of	   50	  minutes.	   All	   results	   expressed	   as	   mean	   ±	   SEM	   (n	   =	   6	   –	   9).	   (P>0.05,	   Student’s	  paired	  t-­‐test).	  
	  
4.3.2	  Functional	  and	  neurological	  outcomes	  of	  stroke	  Stroke	  mice	   displayed	   significant	   neurological	   impairment	   compared	   to	  sham	   mice	   6	   h	   and	   24	   h	   post-­‐stroke	   (Figure	   4.2A,	   P<0.05,	   two-­‐way	   ANOVA	  followed	   by	   Bonferroni	   post-­‐hoc	   test).	   Mice	   did	   not	   show	   a	   difference	   in	  neurological	  impairment	  24	  h	  post-­‐stroke	  compared	  to	  6	  h	  post-­‐stroke	  (P>0.05).	  Stroke	  mice	  had	  a	  reduction	  in	  hanging	  time	  on	  the	  hanging	  wire	  test	  24	  h	  post-­‐stroke,	  compared	  to	  sham	  control	  mice	  (Figure	  4.2B,	  P<0.05,	  Student’s	  unpaired	  t-­‐test).	  Infarct	  and	  oedema	  volumes	  were	  measured	  at	  24	  h	  post-­‐stroke	  (Figure	  4.3).	  Hanging	  wire,	   infarct	  and	  oedema	  analyses	  were	  not	  performed	  at	  6	  h,	  as	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this	   time-­‐point	   is	   too	   early	   to	   see	   changes	   in	   functional	   impairment,	   and	   the	  infarct	   is	   not	   close	   to	   being	   completely	   formed	   at	   6	   h,	   and	   thus	   infarct	  measurements	  would	  not	  be	  indicative	  of	  cerebral	  damage.	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  Figure	  4.2:	  Neurological	  deficit	   scores	   (A,	  n	  =	  6-­‐9)	  6	  h	  and	  24	  h	  post-­‐stroke	  or	  sham	   surgery,	   and	   hanging	   wire	   tests	   (B,	   n	   =	   8-­‐9)	   24	   h	   post-­‐stroke	   surgery.	  Hanging	  wire	  results	  are	  expressed	  as	  mean	  ±	  SEM	  (*P	  <	  0.05	  vs.	  sham,	  Student’s	  unpaired	  t-­‐test),	  neurological	  deficit	  score	  results	  expressed	  as	  median	  (*P<0.05	  vs.	  sham,	  Mann-­‐Whitney	  test)	  .	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4.3.3	  Effect	  of	  stroke	  on	  lung	  inflammation	  There	   was	   a	   significant	   increase	   in	   total	   inflammatory	   cells	   and	  macrophages	   in	   the	  BALF	  at	  6	  h	   following	   stroke	   (Figure	  4.4,	  P<0.05,	   two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐hoc	  test).	   	  However,	  there	  was	  no	  increase	  in	  the	  number	  of	  neutrophils	  or	  lymphocytes	  in	  the	  BALF	  of	  mice	  at	  6	  h	  following	  stroke	   (Figure	   4.4,	   P>0.05).	   	   Interestingly,	   there	  was	   no	   increase	   in	   total	   cells,	  macrophages,	   neutrophils	   or	   lymphocytes	   in	   BALF	   of	   mice	   24	   h	   post-­‐stroke	  compared	  to	  sham	  stroke	  mice	  (Figure	  4.4,	  P>0.05).	  	  Gene	  expression	  of	  IL-­‐6	  and	  MIP-­‐2α	  was	   significantly	   increased	   in	  whole	   lung	   tissue	   of	  mice	   6	   h	   following	  stroke	  (Figure	  4.5,	  P<0.05,	  Student’s	  unpaired	  t-­‐test).	  However,	  no	  changes	  in	  the	  expression	   of	   IL-­‐1β,	   TNF-­‐α,	  MCP-­‐1	   and	  MMP-­‐12	  were	   observed	   in	  whole	   lung	  tissue	  6	  h	  post-­‐stroke	  (Figure	  4.5,	  P>0.05).	  	  Interestingly,	  there	  was	  no	  difference	  in	   IL-­‐6,	  MIP-­‐2α,	   IL-­‐1β,	  TNF-­‐α	  and	  MCP-­‐1	   in	  whole	   lung	   tissue	  24	  h	  post-­‐stroke	  (Figure	  4.5,	  P>0.05).	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  Figure	  4.6:	  mRNA	  expression	  of	  proinflammatory	  genes	   in	  whole	   lung	  tissue	  as	  detected	  by	  qPCR,	  24	  h	  post-­‐stroke.	  All	  results	  are	  expressed	  as	  mean	  ±	  SEM	  (n	  =	  8,	  Student’s	  unpaired	  t	  -­‐	  test)	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experimental	  stroke	  in	  mice	  can	  cause	  lung	  inflammation.	  	  Moreover,	  this	  is	  the	  first	  study	  to	  characterise	  any	  pulmonary	  changes	  in	  this	  animal	  model	  of	  stroke.	  In	  the	  present	  study	  we	  found	  that	  there	  was	  an	  increase	  in	  BALF	  inflammation	  6	  hours	  after	  stroke.	  This	  increase	  in	  BALF	  inflammation	  was	  overwhelmingly	  due	  to	  an	  increase	  in	  macrophages.	  	  Interestingly,	  we	  did	  not	  see	  an	  increase	  in	  MCP-­‐1	  expression,	  a	  key	  chemoattractant	  of	  macrophages,	  at	  any	  time-­‐point	  in	  whole	  lung	   tissue.	   This	   suggests	   that	   other	   chemoattractants	   were	   likely	   to	   be	  responsible	  for	  the	  recruitment	  of	  macrophages	  into	  the	  lungs.	  	  What	   was	   interesting	   in	   the	   current	   study	   was	   that	   there	   was	   a	  significant	  increase	  in	  the	  mRNA	  expression	  of	  MIP-­‐2α,	  a	  chemokine	  secreted	  by	  inflammatory	  cells	  such	  as	  macrophages	  and	  a	  homologue	  of	  human	  IL-­‐8	  (211),	  in	   lung	   tissue	   at	   6	   h	   post-­‐stroke.	   	   It	   is	   well	   known	   that	  MIP-­‐2α	   is	   involved	   in	  initiating	  neutrophilic	  inflammation.(212)	  Neutrophilic	  inflammation	  appears	  to	  play	   a	   key	   role	   in	   the	   development	   of	   ALI	   (213).	   Although	   an	   increase	   in	  neutrophils	  was	  not	  observed	  in	  the	  BALF	  in	  this	  study,	  there	  may	  be	  evidence	  of	  neutrophilic	   inflammation	   in	   lung	   tissue,	   and	   lung	   samples	   have	  been	   kept	   for	  histological	   analysis.	   An	   animal	   study	   of	   traumatic	   brain	   injury	   (TBI)	   found	  evidence	  of	  neutrophil	   infiltration	  and	  ALI	   in	  mouse	   lung	  tissue,	  12	  h	  and	  24	  h	  after	  brain	  injury	  (214).	  	  In	  humans,	  a	  study	  investigating	  the	  occurrence	  of	  lung	  injury	   in	   patients	   with	   fatal	   brain	   injury	   found	   that	   expression	   of	   IL-­‐8	   (a	  neutrophil	   chemoattractant)	   was	   increased	   in	   lung	   tissue,	   and	   an	   increase	   in	  neutrophils	  was	  found	  in	  the	  BALF	  (215).	  It	  is	  interesting	  to	  note	  that	  while	  we	  observed	  an	  increase	  in	  the	  neutrophil	  chemotactic	  factor	  MIP-­‐2α,	  we	  did	  not	  see	  an	  increase	  in	  neutrophils	  in	  the	  BALF	  of	  mice	  6	  h	  post-­‐stroke.	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In	  the	  present	  study	  we	  found	  that	  IL-­‐6	  mRNA	  expression	  in	  whole	  lung	  tissue	  was	  increased	  at	  6	  h	  post-­‐stroke,	  and	  this	  was	  ameliorated	  by	  24	  h	  post-­‐stroke.	   This	   finding	   is	   in	   accord	   with	   studies	   showing	   that	   the	   IL-­‐6	   is	   a	   pro-­‐inflammatory	   cytokine	   involved	   in	   the	   development	   of	   ALI	   (216).	   Increased	  expression	   of	   IL-­‐6	   in	   BALF	   is	   a	   predictor	   of	   mortality	   in	   ALI	   (217).	   Thus,	  regardless	  of	  the	  mechanisms	  responsible	  for	  the	  increased	  BALF	  inflammation	  observed	  6	  hours	  post-­‐stroke,	  results	  from	  this	  experimental	  chapter	  are	  similar	  to	  what	  was	   observed	   clinically,	   suggesting	   that	   ALI	   could	   be	   occurring	   in	   the	  hours	  following	  experimental	  stroke	  in	  mice.	  It	  is	  of	  importance	  that	  this	  earlier	  time-­‐point	   is	   a	   focus	  of	   further	   researchs	   as	   this	  may	  be	  when	   lung	  damage	   is	  occurring	  after	  ischaemic	  stroke.	  Future	  studies	  should	  include	  a	  later	  time-­‐point	  (e.g.	  72	  h)	   to	   investigate	   further	  changes	   to	   the	   lung	   inflammatory	  profile	  after	  ischaemic	  stroke,	  and	   to	  see	   if	   inflammatory	  changes	  are	  sustained	   in	   the	  days	  following	   ischaemic	   neurological	   injury.	   Immunosuppression	   occurs	   after	   the	  initial	  rise	  in	  inflammation	  after	  stroke,	  and	  including	  a	  later	  time-­‐point	  in	  future	  studies	  will	  help	  shed	   light	  on	  how	  this	   immunosuppression	  may	  contribute	   to	  lung	  injury	  and	  susceptibility	  to	  infection.	  ALI	  makes	  the	  lungs	  more	  susceptible	  to	  further	  injury	  and	  infection.	  This	  can	  be	   explained	  by	   the	   “double-­‐hit”	   theory,	  which	   suggests	   that	   the	   lungs	   are	  initially	  “primed”,	  with	  an	  activation	  and	  infiltration	  of	  inflammatory	  cells	  in	  the	  lungs.	   This	   creates	   an	   exaggerated	   response	   to	   a	   secondary	   insult	   such	   as	   an	  infection,	   leading	   to	   further	   injury	   (204,	   218).	   Although	   this	   hasn’t	   been	  investigated	  in	  the	  current	  study,	  further	  characterization	  of	  ALI	  in	  experimental	  stroke	  should	  involve	  testing	  the	  susceptibility	  of	  lungs	  to	  infection	  and	  injury	  in	  the	  days	  after	  stroke.	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A	   common	   feature	  of	   lung	   injury	   following	  neurological	  damage	   is	  NPO.	  The	   current	   theory	   describing	   mechanisms	   leading	   to	   NPO	   is	   that	   initially	  hydrostatic	   pulmonary	   oedema	   occurs	   (leading	   to	   low	   protein	   content	   in	  pulmonary	   fluid),	   and	   that	   damage	   to	   the	   pulmonary	   capillaries	   persists	   after	  normal	   haemodynamics	   are	   restored	   (leading	   to	   high	   protein	   content	   in	  pulmonary	   fluid).	   While	   we	   did	   not	   measure	   the	   protein	   content	   of	   BALF	   of	  stroke	  mice	  in	  the	  current	  study,	  it	  would	  be	  useful	  to	  measure	  protein	  content	  in	   the	   BALF	   in	   future	   studies	   to	   investigate	   the	   occurrence	   of	   NPO	   after	  experimental	   stroke.	   	   Determination	   of	   lung	   wet	   weight	   to	   dry	   weight	   ratio	  should	  also	  be	  made	  in	  future	  as	  a	  gravimetric	  assessment	  of	  pulmonary	  oedema	  (219).	   This	   study	   is	   the	   first	   to	   investigate	   pulmonary	   inflammatory	   changes	  after	   ischaemic	   stroke	   in	   mice,	   as	   an	   initial	   investigation	   into	   ALI	   caused	   by	  ischaemic	  stroke.	  ALI	  and	  NPO	  are	  of	  particular	  importance	  to	  those	  with	  already	  compromised	  lungs,	  such	  as	  COPD	  patients.	  Post-­‐stroke	  mortality	  appears	  to	  be	  higher	   in	   the	   COPD	   population	   compared	   to	   the	   general	   population	   (10).	  Pulmonary	  complications	  such	  as	  ALI	  and	  NPO	  frequently	  occur	  after	  stroke,	  and	  these	  are	  likely	  factors	  contributing	  to	  higher	  mortality	  in	  the	  COPD	  population.	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5.1	  Introduction	  COPD	  is	   increasingly	  being	  recognized	  as	  a	  risk	   factor	   for	  stroke.	  Recent	  studies	   show	   that	   the	   risk	   of	   stroke	   is	   20%	   greater	   in	   COPD	   compared	   to	   the	  general	   population,	   and	   this	   risk	   is	   even	   greater	   following	   an	   AECOPD	   (220).	  There	  is	  also	  some	  evidence	  to	  suggest	  that	  there	  is	  a	  relationship	  between	  COPD	  and	  worse	   stroke	  outcomes	   (10,	  11).	  Patients	  with	  COPD	  are	  at	  greater	   risk	  of	  adverse	   events	   and	   mortality	   following	   a	   stroke	   compared	   to	   those	   without	  COPD.	  However,	  no	  causal	  mechanism	  has	  been	  established	  between	  COPD	  and	  worse	  outcomes	  following	  a	  stroke.	  As	  discussed	  in	  Chapter	  1:	  Introduction,	  it	  is	  plausible	   that	   heightened	   levels	   of	   systemic	   inflammation	   and	   oxidative	   stress	  may	   contribute	   to	   increased	   stroke	   severity	   and	   the	   occurrence	   of	   post-­‐stroke	  adverse	  events.	  	  It	  is	  difficult	  to	  determine	  the	  causal	  mechanisms	  that	  may	  explain	  worse	  outcomes	   following	   a	   stroke	   in	  human	  COPD.	  However,	   one	  way	   to	  potentially	  understand	  the	  mechanistic	  links	  between	  COPD	  and	  stroke	  outcomes	  is	  to	  use	  a	  preclinical	  model	  that	  combines	  COPD	  and	  stroke.	  It	  is	  surprising	  and	  interesting	  that	  no	  animal	  studies	  have	  been	  undertaken	  investigating	  stroke	  in	  the	  context	  of	   COPD.	   The	   preclinical	   mouse	   model	   of	   COPD	   used	   in	   this	   study	   replicates	  many	  aspects	  of	  human	  disease,	  and	  has	  been	  used	  previously	  to	  investigate	  the	  systemic	   changes	   of	   COPD	   (197).	   Briefly,	   the	  model	   involves	   exposing	  mice	   to	  cigarette	  smoke	  over	  a	  period	  of	  weeks	  to	  months,	  depending	  on	  what	  features	  of	  COPD	  want	  to	  be	  modeled.	  Mice	  begin	  to	  develop	  an	  inflammatory	  response	  to	  cigarette	  smoke	  after	  4	  days	  of	  cigarette	  smoke	  exposure,	  and	  begin	  to	  develop	  emphysema	   and	   a	   lung	   phenotype	   comparable	   to	   COPD	   after	   3-­‐6	   months	   of	  exposure	  to	  cigarette	  smoke	  (18).	  This	  model	  typically	  uses	  BALB/c	  mice,	  as	  they	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have	  a	  robust	  response	  to	  the	  cigarette	  smoke.	  The	  current	  study	  will	  investigate	  stroke	   outcomes	   after	   2	   weeks	   (acute),	   8	   weeks	   (sub-­‐chronic)	   and	   12	   weeks	  (chronic)	  of	  cigarette	  smoke	  exposure,	  time-­‐points	  which	  represent	  the	  initiation	  (acute),	  progression	  (8	  weeks)	  and	  development	  (12	  weeks)	  of	  COPD.	  Therefore,	  the	  aim	  of	  this	  experimental	  chapter	  was	  to	  investigate	  stroke	  outcomes	  (functional	  hanging	  wire	  test,	  neurological	  scoring,	  infarct	  and	  oedema	  volume)	   in	  an	  animal	  model	  of	  COPD.	   It	  was	  hypothesized	   that	  COPD/smoking	  will	  worsen	  brain	   injury	  after	   ischaemic	  stroke	   in	  association	  with	  exacerbated	  oxidative	  stress	  and	  inflammation.	  
5.2	  Materials	  and	  methods	  Common	  materials	  and	  solutions	  are	  listed	  in	  General	  Methods	  (Chapter	  2).	  
5.2.1	  Animals	  and	  ethics	  All	   experimental	   procedures	   were	   approved	   by	   the	   Animal	   Ethics	  Committee	   at	  RMIT	  University	   (AEC	  #1532).	   C57BL/6	  mice	  7-­‐12	  weeks	  of	   age	  were	   obtained	   from	   the	   Animal	   Resources	   Centre	   (ARC;	   Perth,	   Australia)	   and	  used	  for	  the	  experiments	  described	  below.	  
5.2.1	  Experimental	  Protocols	  C57BL/6	  mice	   underwent	   cigarette	   smoke	   (CS)	   exposure	   as	   outlined	   in	  Chapter	  2:	  General	  Methods,	  for	  a	  period	  of	  2	  weeks	  (acute	  exposure,	  n	  =	  10	  per	  group),	  8	  weeks	  (sub-­‐chronic	  exposure,	  n	  =	  18	  per	  group)	  or	  12	  weeks	  (chronic	  exposure,	  n	  =	  35	  –	  47	  per	  group).	  Following	  the	  acute	  CS	  exposure	  period,	  mice	  underwent	   tMCAO	   surgery	  with	   an	   ischaemic	   period	   of	   30	  min,	   as	   outlined	   in	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Chapter	  2:	  General	  Methods.	  Regional	  cerebral	  blood	  flow	  was	  measured	  during	  the	   procedure	   for	   all	   animals	   using	   trans-­‐cranial	   laser-­‐Doppler	   flowmetry.	  Following	  the	  sub-­‐chronic	  and	  chronic	  CS	  exposure	  periods,	  mice	  were	  randomly	  assigned	  to	  stroke	  or	  sham	  groups.	  Stroke	  mice	  underwent	  tMCAO	  surgery	  with	  an	   ischaemic	   period	   of	   40	  min.	   Sham	   animals	   underwent	   the	   same	   procedure	  except	  that	  the	  filament	  was	  not	  inserted.	  Functional	  and	  neurological	  tests	  were	  performed	  as	  described	  in	  Chapter	  2:	  General	  Methods,	  just	  prior	  to	  culling.	  Mice	  were	  culled	  via	  anaesthetic	  overdose	  with	  sodium	  pentobarbital	  (240mg/kg),	  24	  h	   following	   the	   induction	  of	   ischaemia.	  Samples	  (blood,	  BALF,	   lungs	  and	  brain)	  were	  collected	  as	  described	  in	  Chapter	  2:	  General	  Methods.	  Mice	  were	  excluded	  from	  analyses	   if	   rCBF	  data	   showed	   they	  did	  not	  meet	   criteria	   for	   a	   ‘successful’	  stroke	   (n	   =	   6	   acute	   exposure;	   n	   =	   6	   sub-­‐chronic	   exposure;	   n	   =	   10	   chronic	  exposure),	  or	  if	  they	  did	  not	  survive	  to	  24	  h	  after	  stroke	  (n	  =	  1	  acute	  exposure;	  n	  =	  4	  sub-­‐chronic	  exposure;	  n	  =	  5	  chronic	  exposure).	  
5.3	  Results	  
5.3.1	  Effect	  of	  cigarette	  smoke	  exposure	  on	  body	  weight	  and	  
lung	  inflammation	  Body	   weight	   was	   lower	   in	   mice	   exposed	   to	   CS	   for	   2,	   8	   and	   12	   weeks	  compared	  to	  sham	  mice	  (Figure	  5.1,	  5.2,	  5.3,	  P<0.05).	  	  Following	   2	   weeks	   of	   CS	   exposure,	   significant	   increases	   in	   neutrophils	  and	   lymphocytes	   were	   observed	   in	   BALF	   (P<0.05,	   Student’s	   unpaired	   t-­‐test),	  although	   there	   was	   no	   significant	   increase	   in	   total	   cell	   counts	   or	   macrophage	  counts	   (P>0.05;	   Figure	   5.4).	   However,	   following	   8	   weeks	   of	   CS	   exposure,	  significant	   increases	   in	   all	   inflammatory	   cell	   types	   (totals,	   macrophages,	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neutrophils,	  lymphocytes)	  were	  observed	  in	  the	  BALF	  (P<0.05,	  two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐hoc	  test;	  Figure	  5.5).	  Stroke	  did	  not	  cause	  a	  further	  increase	   on	   inflammatory	   cell	   counts,	   which	   is	   consistent	   with	   findings	   in	  Chapter	  4	  at	  24	  h.	  After	  12	  weeks	  of	  CS	  exposure,	  increases	  in	  all	  inflammatory	  cell	  types	  were	  observed	  in	  the	  BALF,	  however	  this	  was	  only	  significant	  for	  total	  cells,	  macrophages	  and	  neutrophils	  in	  the	  smoke	  +	  sham	  surgery	  group,	  and	  only	  total	  cell	  counts	  in	  the	  smoke	  +	  stroke	  surgery	  group	  (P<0.05,	  two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐hoc	  test;	  Figure	  5.6).	  	  
	  Figure	   5.1:	   Effect	   of	   cigarette	   smoke	   exposure	   on	   body	   weight.	   Mice	   were	  exposed	  to	  cigarette	  smoke	  (n	  =	  10)	  or	  sham	  smoke	  (n	  =	  10)	  for	  2	  weeks.	  	  Results	  are	   expressed	   as	   mean	   ±	   SEM	   (Student’s	   unpaired	   t-­‐test	   performed	   on	   final	  weights,	  *P<0.05	  vs	  sham-­‐exposed	  control	  group).	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  Figure	   5.2:	   Body	   weight	   across	   8-­‐week	   smoke	   exposure	   period.	   Mice	   were	  exposed	  to	  cigarette	  smoke	  (n	  =	  18)	  or	  sham	  smoke	  (n	  =	  18)	  for	  8	  weeks.	  Results	  expressed	  as	  mean	  ±	  SEM	  (Student’s	  unpaired	  t-­‐test	  performed	  on	  final	  weights,	  *P<0.05	  vs	  sham-­‐exposed	  control	  group).	  
	  Figure	   5.3:	   Effect	   of	   12	   week	   smoke	   exposure	   on	   body	   weight.	   Mice	   were	  exposed	   to	   cigarette	   smoke	   (n	   =	   47)	   or	   sham	   smoke	   (n	   =	   35)	   for	   12	   weeks.	  Results	  expressed	  as	  mean	  ±	  SEM	  (Student’s	  unpaired	  t-­‐test	  performed	  on	  final	  weights,	  *P<0.05	  vs	  sham-­‐exposed	  control	  group).	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  Figure	   5.6:	   Effect	   of	   12	  weeks	   cigarette	   smoke	   exposure	   on	   inflammatory	   cell	  counts	   in	   bronchoalveolar	   lavage	   fluid	   (BALF).	   Total	   (A),	   macrophage	   (B),	  neutrophil	  (C)	  and	  lymphocyte	  (D)	  cell	  counts	  are	  shown	  as	  mean	  ±	  SEM	  (n	  =	  4-­‐	  8,	   *P<0.05	   vs	   sham-­‐exposed	   control	   group,	   two-­‐way	   ANOVA	   followed	   by	  Bonferroni	  post-­‐hoc	  test)	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  Figure	   5.7:	   Regional	   cerebral	   blood	   flow	   during	   tMCAO	   surgery	   and	   during	  reperfusion,	   following	   2	   weeks	   of	   cigarette	   smoke	   exposure	   or	   sham	   smoke	  (room	  air)	  exposure	  (n	  =	  8	  –	  10).	  (P>0.05,	  Student’s	  paired	  t-­‐test).	  
	  Figure	   5.8:	   Regional	   cerebral	   blood	   flow	   during	   tMCAO	   surgery	   and	   during	  reperfusion,	   following	   8	   weeks	   of	   cigarette	   smoke	   exposure	   or	   sham	   smoke	  (room	  air)	  exposure	  (n	  =	  5	  –	  7).	  (P>0.05,	  Student’s	  paired	  t-­‐test).	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  Figure	   5.9:	   Regional	   cerebral	   blood	   flow	   during	   tMCAO	   surgery	   and	   during	  reperfusion,	   following	   12	   weeks	   of	   cigarette	   smoke	   exposure	   or	   sham	   smoke	  exposure	   (room	   air)	   (n	   =	   8	   –	   10,	   Student’s	   paired	   t-­‐test	   performed	   on	   final	  values,	  *P<0.05	  vs	  sham-­‐exposed	  control	  group).	  
	  5.3.3	  Effect	  of	  cigarette	  smoke	  exposure	  on	  stroke	  outcomes	  All	  stroke	  groups	  displayed	  some	  degree	  of	  neurological	  deficit	  24	  h	  after	  stroke.	   Neurological	   deficit	   scores	   in	   experimental	   stroke	   groups	   were	  significantly	   different	   from	   sham	   surgery	   control	   groups	   in	   the	   sub-­‐chronic	   (8	  weeks)	   and	   chronic	   (12	   weeks)	   CS	   exposure	   studies	   (Figure	   5.10;	   P<0.05,	  Student’s	   t-­‐test	   or	   two-­‐way	   ANOVA	   followed	   by	   Bonferroni	   post-­‐hoc	   test).	  Cigarette	  smoke	  appeared	   to	  have	  no	  effect	  on	  neurological	  deficit	   scores	  after	  acute,	   sub-­‐chronic	   or	   chronic	   exposure.	   All	   stroke	   groups	   had	   a	   reduction	   in	  hanging	  time	  on	  the	  hanging	  wire	  test,	  and	  this	  was	  significantly	  different	  from	  sham	   surgery	   control	   groups	   in	   the	   sub-­‐chronic	   and	   chronic	   smoke	   exposure	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studies	   (Figure	   5.10;	   P<0.05,	   Student’s	   t-­‐test	   or	   two-­‐way	   ANOVA	   followed	   by	  Bonferroni	  post-­‐hoc	  test).	  	  
	  Figure	  5.10:	  Neurological	  deficit	   (A,	  B,	  C)	  and	   functional	  hanging	  wire	   (D,	  E,	  F)	  scores	  24	  h	  post-­‐stroke	  or	  sham	  surgery.	  Mice	  were	  exposed	  to	  2	  (A,	  D;	  n	  =	  8-­‐11),	  8	  (B,	  E;	  n=	  5	  -­‐	  8)	  or	  12	  (C,	  F;	  n	  =	  8	  -­‐	  18)	  weeks	  of	  cigarette	  smoke	  or	  sham	  smoke	  (room	  air)	  prior	  to	  sham	  or	  stroke	  surgery.	  All	  results	  are	  expressed	  as	  mean	  ±	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SEM.	   (*P<0.05	   vs.	   sham,	   Student’s	   t-­‐test	   or	   two-­‐way	   ANOVA	   followed	   by	  Bonferroni	  post-­‐hoc	  test).	  
5.3.4	  Effect	  of	  cigarette	  smoke	  exposure	  on	  infarct	  and	  oedema	  No	  differences	  in	  infarct	  volume	  were	  observed	  between	  smoke	  and	  sham	  groups	   after	   2,	   8	   or	   12	  weeks	   of	   CS	   exposure.	   There	  was	   a	   trend	   for	   oedema	  volumes	   to	  be	   lower	   in	   smoke	  exposed	  groups	   compared	   to	   controls,	   however	  this	  difference	  was	  not	  significant	  (P>0.05,	  Figure	  5.11).	  	  
	   70	  
	  Figure	   5.11:	   Cerebral	   infarct	   and	   oedema	   volumes	   at	   24	   h	   after	   tMCAO	  procedure.	  Mice	  were	  exposed	  to	  2	  (A,	  D;	  n	  =	  5	  -­‐	  10),	  8	  (B,	  E;	  n	  =	  5)	  or	  12	  (C,	  F;	  n	  =	   6	   -­‐	   8)	   weeks	   of	   cigarette	   smoke	   or	   sham	   smoke	   (room	   air)	   prior	   to	   stroke	  surgery.	  All	  results	  are	  expressed	  as	  mean	  ±	  SEM	  (Student’s	  unpaired	  t-­‐test).	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worse	   stroke	   outcomes	   in	   mice.	   However,	   this	   study	   found	   that	   although	   CS	  exposure	  caused	  its	  expected	  effects	  on	  body	  weight	  (i.e.	  reduced	  body	  weight)	  and	  lung	  inflammation	  (i.e.	  increase	  in	  lung	  inflammation),	  there	  was	  no	  effect	  on	  stroke	  outcomes.	  Cigarette	  smoke	  exposure	  causes	  an	  immediate	  inflammatory	  response	  in	  the	   lungs,	   by	   triggering	   the	   activation	   of	   proinflammatory	   mediators	   such	   as	  TNF-­‐α	  NFκB	  and	  MMP-­‐12.	  This	  results	  in	  the	  recruitment	  of	   inflammatory	  cells	  such	   as	   neutrophils,	   macrophages	   and	   lymphocytes	   into	   the	   lungs,	   and	   this	  immune	  response	  contribute	  to	  the	  damage	  of	   lung	  tissue	  (189).	  After	  2,	  8	  and	  12	   weeks	   of	   CS	   exposure	   inflammatory	   cells	   were	   elevated	   in	   the	   BALF,	  indicating	  that	  that	  lung	  inflammation	  was	  present	  in	  these	  mice.	  However,	  these	  cell	  counts	  after	  2	  weeks	  of	  CS	  exposure	  were	   lower	  than	  what	  has	  historically	  been	  seen	  in	  the	  BALB/c	  mouse	  strain	  in	  response	  to	  CS	  (189)	  after	  4	  days.	  We	  have	  previously	  shown	  that	  the	  C57BL/6	  mouse	  strain	  is	  more	  resistant	  to	  acute	  CS-­‐induced	  lung	  inflammation	  compared	  to	  the	  BALB/c	  mouse	  strain	  (189,	  221).	  In	  light	  of	  this,	  we	  extended	  the	  cigarette	  smoke	  exposure	  period	  out	  to	  8	  (sub-­‐chronic	  protocol)	  and	  12	  (chronic	  protocol)	  weeks.	  Cigarette	   smoke	   exposure	   led	   to	   a	   reduction	   in	   body	   weight	   across	   all	  three	   time-­‐points	   (2,	  8	  and	  12	  weeks).	  Nicotine,	  a	  primary	  constituent	  of	  CS,	   is	  known	   to	   suppress	   appetite.	   Although	  we	   did	   not	  measure	   food	   intake	   in	   our	  study,	  we	  have	  previously	  shown	  that	  CS-­‐exposed	  mice	  eat	  less	  (222)	  However,	  studies	  have	  shown	  that	  the	  weight	  loss	  in	  response	  to	  CS	  is	  not	  solely	  due	  to	  a	  reduction	  in	  appetite,	  but	  that	  other	  metabolic	  pathways	  are	  also	  involved,	  such	  as	  decreases	   in	  energy	   intake,	   increases	   in	  energy	  expenditure	  and	  accelerated	  proteolysis	  (223,	  224).	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I	  then	  went	  on	  to	  explore	  stroke	  outcomes	  in	  mice	  that	  had	  been	  exposed	  to	  cigarette	  smoke	  for	  2,	  8	  and	  12	  weeks.	  	  Despite	  increased	  lung	  inflammation	  in	  these	  CS-­‐exposed	  mice,	   it	  was	  surprising	   that	  we	  did	  not	  see	  changes	   in	  any	  of	  the	  measured	  stroke	  outcomes,	  including	  neurological	  deficit	  score,	  hanging	  wire	  test,	   infarct	   and	   oedema	   volumes,	   given	   that	   there	   is	   increasing	   evidence	   to	  suggest	   that	   COPD	   is	   associated	   with	   worse	   outcomes	   following	   stroke	   in	  humans(10).	   It	  has	  been	   suggested	   that	   this	  may	  be	  due	   to	   increased	   systemic	  inflammation	   and	   oxidative	   stress	  making	   the	   brain	  more	   susceptible	   to	   brain	  injury,	   and	   the	   whole	   body	   more	   susceptible	   to	   adverse	   events	   following	   a	  stroke.	  My	  data	  suggests	  that	  the	  mouse	  model	  of	  COPD	  used	  in	  this	  study	  (i.e.	  2,	  8	   and	   12	  weeks	   of	   CS	   exposure)	   has	   no	   effect	   on	   stroke	   severity.	   There	   are	   a	  number	  of	  possible	  reasons	  why	  stroke	  severity	  was	  not	  worse	  in	  this	  study:	  (i)	  12	  weeks	  of	  CS	  exposure	  may	  have	  been	  insufficient	  to	  induce	  systemic	  changes	  believed	   to	   play	   a	   key	   role	   in	   worsened	   stroke	   outcomes,	   (ii)	   COPD	   may	   not	  directly	   lead	   to	   worsened	   stroke	   severity,	   but	   may	   make	   an	   individual	   more	  susceptible	  to	  post-­‐stroke	  complications	  and	  adverse	  events,	  and	  (iii)	  COPD	  may	  increase	  risk	  but	  play	  no	  role	  in	  stroke	  severity.	  Another	   important	   point	   to	   consider	   is	   that	   all	  mice	   in	   this	   study	  were	  culled	   24	   h	   post-­‐stroke.	   	   At	   this	   time-­‐point,	   the	   cerebral	   infarct	   is	   almost	   fully	  formed	  (~70-­‐80%)	  and	  we	  can	  assess	  stroke	  severity	  (225).	   	  However,	   it	  could	  be	  that	  stroke	  outcomes	  were	  not	  different	  in	  CS-­‐exposed	  mice	  because	  the	  time	  at	   which	  we	   assessed	   stroke	   outcomes	  were	   too	   soon	   (i.e	   24	   hours)	   and	   that	  outcomes	   should	   be	   assessed	   at	   later	   time	   points	   (e.g.	   >72	   hours)	   when	   the	  infarct	   is	   fully	   developed(225).	   	   Therefore,	   to	   assess	   long-­‐term	  outcomes	   after	  stroke,	  which	   are	  more	   clinically	   relevant,	   future	   experiments	   should	   compare	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stroke	  outcomes	   in	  the	  days	  and	  weeks	   following	  experimental	  stroke	   in	  COPD	  mice	   and	   non-­‐COPD	   mice.	   This	   will	   allow	   us	   to	   investigate	   the	   mechanisms	  leading	  to	  an	  increased	  mortality	  following	  a	  stroke	  in	  patients	  with	  COPD.	  	  Future	   experiments	   will	   require	   an	   assessment	   of	   the	   systemic	  inflammation	   and	   oxidative	   stress	   in	   C57BL/6	  mice	   after	   CS	   exposure.	   	   Blood	  samples	   were	   collected	   from	   mice	   used	   in	   this	   study;	   however	   time	   was	   not	  permitting	   for	   an	   analysis	   to	   occur.	   The	   CS	   exposure	   period	   may	   need	   to	   be	  lengthened	   for	   C57BL/6	   mice,	   as	   they	   are	   not	   as	   sensitive	   to	   CS-­‐induced	  inflammation	   as	   the	   BALB/c	   mouse	   strain,	   and	   systemic	   changes	   may	   not	   be	  occurring	  after	  12	  weeks	  of	  cigarette	  smoke	  exposure.	  Finally,	   it	   is	   possible	   that	   COPD	  may	   not	   impact	   on	   stroke	   severity,	   but	  may	   just	   increase	   the	   risk	   of	   stroke.	   The	   model	   of	   stroke	   used	   in	   this	   study	  cannot	   be	   used	   to	   investigate	   risk;	   however	   it	   can	   be	   used	   to	   investigate	  mechanisms	   and	  physiological	   changes	   that	  would	   likely	   increase	   the	   risk	   of	   a	  stroke.	   It	   is	   known	   that	   CS	   increases	   the	   risk	   of	   stroke	   through	   a	   number	   of	  mechanisms,	   such	   as	   hypercoagulability	   and	   increased	   immunoreactivity	   in	  atherosclerotic	   plaques.	   These	   changes	   may	   be	   sustained	   in	   COPD.	   Future	  studies	  will	   investigate	  cardiovascular	  changes	   in	   this	  preclinical	  animal	  model	  of	  COPD,	  which	  may	  elicit	  an	  increased	  risk	  of	  stroke.	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This	   thesis	  has	  systematically	  examined	  (i)	  strain-­‐dependant	  differences	  of	  BALB/c	  and	  C57BL/6	  mice	  in	  response	  to	  an	  experimental	  model	  of	  transient	  ischaemic	  stroke	  (tMCAO)	  (Chapter	  3),	  (ii)	  changes	  in	  markers	  of	  lung	  injury	  in	  mice	   following	   experimental	   stroke	   (Chapter	   4)	   and	   (iii)	   changes	   in	   stroke	  outcomes	   in	  C57BL/6	  mice	  exposed	  acutely	  and	  chronically	   to	  cigarette	  smoke	  (preclinical	  mouse	  model	  of	  COPD)	  (Chapter	  5)	  The	  purpose	  of	  investigating	  the	  strain-­‐dependent	  differences	  of	  BALB/c	  and	  C57BL/6	  mice	  in	  response	  to	  an	  experimental	  model	  of	  transient	  ischaemic	  stroke	   (Chapter	   3)	   was	   to	   identify	   the	   most	   suitable	   strain	   of	   mouse	   for	   the	  effects	  of	  COPD	  on	  stroke	  outcomes	  (Chapter	  5).	   	  The	  BALB/c	  mouse	  strain	  has	  been	   used	   for	   many	   COPD	   studies,	   as	   its	   response	   to	   cigarette	   smoke	  mimics	  many	  aspects	  of	  human	  disease.	   	  However,	  BALB/c	  mice	  are	  not	   typically	  used	  for	  experimental	  stroke	  studies	  (unlike	  the	  use	  of	  C57BL/6	  mice),	  and	  as	  such	  we	  needed	   to	   characterize	   their	   response	   to	   ischaemic	   stroke	  prior	   to	  a	   long-­‐term	  study	   on	   the	   effect	   of	   COPD	   on	   ischaemic	   stroke	   outcomes.	   	   Results	   from	   the	  mouse	  strain	  comparison	  study	  (C57BL/6	  vs.	  BALB/c)	  demonstrated	  that	  there	  were	  few	  differences	  between	  the	  strains	  in	  terms	  of	  measured	  stroke	  outcomes,	  however	   the	  mortality	   rate	   in	   the	  BALB/c	  mouse	   strain	  was	  much	  higher	   than	  the	  C57BL/6	  mouse	  strain.	  	  Due	  to	  these	  results,	  it	  was	  decided	  that	  the	  BALB/c	  mouse	   strain	   would	   be	   unsuitable	   for	   further	   experiments,	   and	   the	   C56BL/6	  mouse	  strain	  would	  be	  used	  to	  study	  the	  effect	  of	  COPD	  on	  stroke	  outcomes.	  Respiratory	  complications	  after	  stroke	  frequently	  occur.	  Acute	  lung	  injury	  (ALI)	   and	  neurogenic	   pulmonary	   oedema	   (NPO)	  have	   scarcely	   been	   studied	   in	  the	   context	   of	   ischaemic	   stroke	   despite	   pulmonary	   complications	   being	   a	  significant	   contributor	   to	   morbidity	   and	   mortality.	   This	   project	   investigated	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inflammatory	   changes	   in	   the	   lungs	   after	   experimental	   stroke	   in	   mice	   as	   a	  preliminary	   investigation	   into	   the	   pulmonary	   changes	   that	   occur	   following	  ischaemic	   stroke	   (Chapter	   4).	   This	   study	   found	   that	   an	   increase	   in	   lung	  inflammation	  occurs	  shortly	  after	  ischaemic	  stroke	  in	  mice.	  A	  increase	  in	  MIP-­‐2α	  mRNA	  expression	  was	  observed	  in	  lung	  tissue	  at	  6	  h	  post-­‐stroke,	  and	  an	  increase	  in	  macrophages	  was	  observed	  6	  h	  after	  stroke.	  Further	  work	  needs	  to	  be	  done	  to	  characterize	   the	   extent	   of	   lung	   injury	   that	   occurs	   after	   experimental	   ischaemic	  stroke.	   Lung	   tissue	   sections	   have	   been	   kept	   for	   histological	   analysis,	   to	  investigate	  the	  degree	  of	  neutrophil	  infiltration	  into	  the	  lungs.	  This	  study	  was	  the	  first	  to	  investigate	  outcomes	  of	  ischaemic	  stroke	  in	  an	  animal	  model	  of	  COPD	  (Chapter	  5).	  An	  increasing	  number	  of	  studies	  are	  showing	  an	  association	  between	  COPD	  and	  risk	  of	  stroke,	  and	  worse	  stroke	  outcomes	  (9-­‐11,	   220).	   Although	   the	   mechanisms	   underlying	   increased	   risk	   of	   stroke,	   and	  worse	   stroke	   outcomes,	   in	   COPD	   are	   unknown,	   the	   effect	   of	   COPD	   on	   stroke	  outcomes	  may	  in	  part	  be	  due	  to	  an	  increased	  level	  of	  systemic	  inflammation	  and	  oxidative	   stress	   in	   individuals	  with	   COPD.	   	   It	  was	   therefore	   hypothesized	   that	  worse	  outcomes	  will	  be	  observed	  after	   ischaemic	  stroke	   in	  an	  animal	  model	  of	  COPD,	  compared	  to	  healthy	  mice.	   	  However,	  the	  results	  from	  this	  study	  suggest	  that	   this	   is	   not	   the	   case,	   as	   chronic	   cigarette	   smoke	   exposure	   did	   not	   worsen	  stroke	  outcomes.	  	  A	  few	  possible	  reasons	  for	  this	  could	  be:	  (i)	  the	  animal	  model	  of	   COPD	   used	   in	   this	   study	   may	   have	   been	   insufficient	   to	   induce	   systemic	  changes	  believed	  to	  play	  a	  key	  role	  in	  worsened	  stroke	  outcomes,	  (ii)	  COPD	  may	  not	  directly	  lead	  to	  worsened	  stroke	  severity,	  but	  may	  make	  an	  individual	  more	  susceptible	  to	  post-­‐stroke	  complications	  and	  adverse	  events,	  and	  (iii)	  COPD	  may	  increase	  risk	  but	  play	  no	  role	  in	  stroke	  severity.	  	  Therefore,	  future	  studies	  should	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look	  at	  extending	  the	  duration	  of	  cigarette	  smoke	  exposure	  (i.e.	  >	  12	  weeks)	  for	  C57BL/6	  mice,	   as	   these	  mice	   are	   typically	   not	   as	   sensitive	   to	   cigarette	   smoke	  exposure	  as	  the	  BALB/c	  mouse	  strain.	  	  	  In	   addition,	   the	   bloods	   collected	   from	   this	   study	   should	   be	   assayed	   for	  systemic	   inflammatory	   markers	   and	   oxidative	   stress	   to	   see	   if	   12	   weeks	   of	  cigarette	   smoke	   was	   indeed	   elevating	   systemic	   inflammation	   and	   oxidative	  stress	   in	   C57BL/6	  mice.	   It	   could	   be	   that	  we	   didn’t	   see	  worse	   stroke	   outcomes	  after	  12	  weeks	  cigarette	  smoke	  exposure	  because	  this	  period	  of	  smoke	  exposure	  was	   insufficient	   to	   elevate	   systemic	   inflammation	   and	   oxidative	   stress.	   In	  addition,	  all	  mice	   in	  this	  study	  were	  culled	  24	  h	  post-­‐stroke.	  At	  this	  time-­‐point,	  the	  cerebral	  infarct	  is	  almost	  fully	  formed	  and	  we	  can	  assess	  stroke	  severity.	  To	  assess	   long-­‐term	   outcomes	   after	   stroke,	   which	   are	   more	   clinically	   relevant,	  future	   experiments	   should	   compare	   stroke	   outcomes	   in	   the	   days	   and	   weeks	  following	  experimental	  stroke	  in	  COPD	  mice	  and	  non-­‐COPD	  mice.	  This	  will	  allow	  us	   to	   investigate	   the	  mechanisms	   leading	   to	  an	   increased	  mortality	   following	  a	  stroke	  in	  patients	  with	  COPD.	  In	  conclusion,	  this	  project	  found	  that	  (i)	  BALB/c	  mice	  had	  a	  high	  mortality	  rate	   in	   response	   to	   tMCAO	   compared	   to	   C57BL/6	   mice,	   (ii)	   experimental	  ischaemic	   stroke	   leads	   to	   an	   inflammatory	   response	   in	   the	   lungs,	   although	  further	   work	   is	   needed	   to	   characterize	   the	   pulmonary	   outcomes	   of	   ischaemic	  stroke,	  and	  (iii)	   the	  selected	  preclinical	  animal	  model	  of	  COPD	  had	  no	  effect	  on	  stroke	  outcomes.	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